Summary.
This review is an attempt to illustrate the diversity of peptides reported for a potential or an established use in cancer therapy. With 612 references, this work aims at covering the patents and publications up to year 2000 with many inroads in years 2001–2002. The peptides are classed according to four categories of effective (or plausible) biological mechanisms of action: receptor—interacting compounds; inhibitors of protein-protein interaction; enzymes inhibitors; nucleic acid—interacting compounds. The fifth group is made of the peptides for which no mechanism of action has been found yet. Incidentally this work provides an overview of many of the modern targets of anticancer research.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abato P, Yuen CM, Cubanski JY, Seto CT (2002) Inhibitors of plasmin that extend into both the S and S' binding sites: cooperative interactions between S1 and S2. J Org Chem 67: 1184–1191
Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615–2622
Aggen JB, Humphrey JM, Gauss CM, Huang HB, Nairn AC, Chamberlin AR (1999) The design, synthesis, and biological evaluation of analogues of the serine-threonine protein phosphatase 1 and 2A selective inhibitor microcystin LA: rational modifications imparting PP1 selectivity. Bioorg Med Chem 7: 543–564
Ahuja D, Vera MD, SirDeshpande BV, Morimoto H, Williams PG, Joullié MM, Toogood PL (2000) Inhibition of protein synthesis by didemnin B: how EF-1a mediates inhibition of translocation. Biochemistry 39: 4339–4346
Akedo H, Isoai A, Hama Y, Kumagai H (1991) Novel polypeptides as cancer metastasis inhibitors. Patent JP 03,34,993. See Chem Abstr 115: 22221t
Albericio F, Giralt E, Jimenez JC, Lopez A, Manzanares I, Rodrigues I, Royo M (2002) Preparation of kahalalide compounds. Patent WO 01 58,934. See Chem Abstr 135: 167039n
Albert R, Smith—Jones P, Stolz B, Simeon C, Knecht H, Bruns C, Pless J (1998) Direct synthesis of [DOTA—DPhe1]—octreotide and [DOTA—DPhel, Tyr3]—octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nucleides to somatostatin receptor positive tumors in man. Bioorg Med Chem Lett 8: 1207– 1210
Andersen RJ, Coleman JE, Piers E, Wallace D (1997) Total synthesis of (-)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity. Tetrahedron Lett 38: 317–320
Andersen R, Piers E, Nieman J, Coleman J, Roberge M (1999) Hemiasterlin analogs. Patent WO 99 32,509. See Chem Abstr 131: 59140X
Anderson HJ, Coleman JE, Andersen RJ, Roberge M (1997) Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 39: 223–226
Andreasen PA, Kjoller L, Christense L, Duffy M (1997) The urokinase- type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22
Angiolillo A, Desgro A, Marsili V, Panara F, Gianfranceschi GL (1993) Synthetic octapeptide pyroGLU-ASP-ASP-SER-ASPGLU- GLU-ASN controls DNA transcription in vitro by RNA polymerase II. Experientia 49: 902–905
Anthony NJ, Desholms SJ, Gomez RP, Graham SL, Hutchinson JH, Stokker GE (1996) Preparation of peptide analogs as thiol-free inhibitors of farnesyl-protein transferase. Patent WO 96 10,034. See Chem Abstr 125: 143311n
Aoyagi T, Ishizuka M, Takeuchi T, Umezawa H (1977) Enzyme inhibitors in relation to cancer therapy. Jpn J Antibiot 30 [Suppl]: 122–132
Aoyama T, Satoh T, Yonemoto M, Shibata J, Nonoshita K, Arai S, Kawakami K, Iwasawa Y, Sano H, Tanaka K, Monden Y, Kodera T, Arakawa H, Suzuki-Takahashi I, Kamei T, Tomimoto K (1998) A new class of highly potent farnesyl diphosphatecompetitive inhibitors of farnesyltransferase. J Med Chem 41: 143–147
Arnold E, Clardy J (1981) Crystal and molecular structure of BBM-928 A, a novel antitumor antibiotic from Actinomadura luzonensis. J Am Chem Soc 103: 1243–1244
Asai A, Hasegawa A, Ochiai K, Yamashita Y, Mizukami T (2000) Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp. J Antibiot 53: 81–83
Asai T, Nagatsuka M, Kuromi K, Yamakawa S, Kurohane K, Ogino K, Tanaka M, Taki T, Oku N (2002) Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. FEBS Lett 510: 206–210
Bae D-G, Gho Y-S, Yoon W-H, Chae C-B (2000) Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 275: 13588–13596
Bai R, Durso NA, Sackett DL, Hamel E (1999) Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38: 14302–14310
Bai R, Verdier-Pinard P, Gangwar S, Stessman CC, McClure KJ, Sausville EA, Pettit GR, Bates RB, Hamel E (2001) Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. Mol Pharmacol 59: 462– 469
Bai R, Covell DG, Liu C, Ghosh AK, Hamel E (2002) (-)doliculide, a new macrocyclic depsipeptide enhancer of actin assembly. J Biol Chem 277: 32165–32171
Balazs A, Szirtes T, Schon I, Kisfaludy L (1992) Preparation of pyroaminoadipate-containing peptide as an epidermal cell proliferation inhibitor. Patent EP 475,657. See Chem Abstr 117: 8496w
Ball KL, Lain S, Fåhraeus R, Smythe C, Lane DP (1996) Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 7: 71– 80
Bandara L, Girling R, La Thangue N (1997) Apoptosis induce in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor. Nat Biotechnol 15: 896–901
Bardelli A, Longati P, Grmaglia D, Stella MC, Comoglio PM (1997) Gabl coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene 15: 3103–3111
Bardelli A, Longati P, Williams TA, Benvenuti S, Comoglio PM (1999) A peptide representing the carboxyl-terminal tail of the Met receptor inhibits kinase activity and invasive growth. J Biol Chem 274: 29274–29281
Barnard D, Sun H, Baker L, Marshall MS (1998) In vitro inhibition of Ras-Raf association by short peptides. Biochem Biophys Res Commun 247: 176–180
Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, Hadcock JR (1996) Identification and characterization of a novel somatostatin antagonist. Mol Pharmacol 50: 709–715
Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, Hadcock JR (1997) Identification and characterization of a novel somatostatin antagonist, erratum. Mol Pharmacol 51: 170
Bates RB, Brusoe KG, Burns JJ, Caldera S, Cui W, Gangwar S, Gramme MR, McClure KJ, Rouen GP, Schadow H, Stessman CC, Taylor SR, Vu VH, Yarick GV, Zhang J, Pettit GR, Bontems R (1997) Dolastatins 26. Synthesis and stereochemistry of dolastatin 11. J Am Chem Soc 119: 2111–2113
Battey J, Wada E (1991) Two distinct receptor subtypes for mammalian bombesin-like peptides. Trends Neurosci 14: 524–528
Battistini C, Giordano P, De Rosa S, Coradi F, Comoglio P, Bardelli A (1997) Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use. Patent WO 97 30,079. See Chem Abstr 127: 234615x
Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petchr TJ, Pless J (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140
Berezov A, Zhang H-T, Greene MI, Murali R (2001) Disabling ErbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J Med Chem 44: 2565– 2574
Bernadi E, Fauchere JL, Atassi G, Viallfont P, Lazaro R (1993) Antitumoral cyclic peptide analogues of chlamydocin. Peptides 14: 1091–1093
Bessodes M, Antonakis K, Herscovici J, Garcia M, Rochefort H, Capony F, Lelievre Y, Scherman D (1999) Inhibition of cathepsin D by tripeptids containing statine analogs. Biochem Pharmacol 58: 329–333
Bewley CA, He H, Williams DH, Faulkner DJ (1996) Acicultins A–C: cytotoxic and antifungal cyclic peptides from the lithistid sponge Aciculites orientalis. J Am Chem Soc 118: 4314–4321
Binétruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Poluët J, Derbin C, Perret G, Mazié JC (2000) factor (VEGF)-mediated angiogenesis. EMBO J 19: 1525–1533
Blanco-Aparicio C, Molina MA, Fernández-Salas E, Frazier ML, Mas JM, Querol E, Avilés FX, de Llorens R (1998) Potato carboxypeptidase inhibitors, a T-knot protein is an epidermal growth factor antagonist that inhibits tumor cell growth. J Biol Chem 273: 12370–12377
Blaschuk OW, Gour BJ, Farookhi R (2002) Compounds and method for cancer therapy using cadherin cell recognition cyclic peptides. Patent US 6,417,325. See Chem Abstr 137: 88441a
Blasi F, Fazioli F, Resnati M, Nicolai S (1998) Peptides mimicking uPAR and having chemotactic activity and therapeutic use of thereof. Patent WO 98 42,733. See Chem Abstr 129: 270635d
Boehm HJ, Daum L, Haupt A, Schmied B, Walker N, Zechel JC (1990a) Preparation of low molecular weight peptides with tumor necrosis factor (TNF) activity. Patent DE 3,841,768. See Chem Abstr 113: 232082h
Boehm HJ, Daum L, Haupt A, Schmied B, Walker N, Zechel JC (1990b) Preparation of peptides as tumor necrosis factor agonistsantagonists. Patent DE 3,841,767. See Chem Abstr 113: 232079n
Boehm HJ, Daum L, Haupt A, Schmied B, Walker N, Zechel JC (1990c) Preparation of tumor necrosis factor analogs. Patent DE 3,841,763. See Chem Abstr 113: 232081g
Bogden AE, Taylor JE, Moreau JP, Coy DH, LePage DJ (1990) Response of the human lung tumor xenografts to treatment with a somatostatin analogue (somatuline). Cancer Res 50: 4360–4365 Boger DL, Ichikawa S (2000) Total syntheses of thiocoraline and BE-22179: establishment of relative and absolute stereochemistry. J Am Chem Soc 122: 2956–2957
Boger DL, Saionz KW (1999) DNA binding properties of key sandramycin analogues: systematic examination of the intercalation chromophore. Bioorg Med Chem 7: 315–321
Boger DL, Chen JH, Saionz KW, Jin Q (1998) Synthesis of key sandramycin analogs: systematic examination of the intercalation chromophore. Bioorg Med Chem 6: 85–102
Boger DL, Ledeboer MW, Kume M, Searcey M, Jin Q (1999) Total synthesis and comparative evaluation of Luzopeptin A-C and Quinoxapeptin A-C. J Am Chem Soc 121: 11375–11388
Bogusky MJ, Culberson JC, Pitzenberger SM, Garsky VM, Wallace A, Pessi A, Koblan KS (1999) Conformation of a novel tetrapeptide inhibitor NH2-D-Trp-D-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase. J Pept Res 54: 66–73
Bonfanti M, Taverna S, Salmona M, D’Incalci M, Broggini M (1997) P21WAF1 derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 57: 1442–1446
Bonnington LS, Tanaka J, Higa T, Kimura J, Yoshimura Y, Nakao Y, Yoshida WY, Scheuer PJ (1997) Cupolamide A: a cytotoxic cyclic heptapeptide from two samples of the sponge Theonella cupola. J Org Chem 62: 7765–7767
Böttger V, Böttger A, Howard SF, Picksley SM, Chène P, García- Echeverría C, Hochkeppel HK, Lane DP (1996) Identification of novel Mdm2 binding peptides by phage display. Oncogene 13: 2141–2147 Böttger V, Böttger A, García-Echeverría C, Chène P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP (1997) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269: 744
Bousquet C, Puente E, Buscail L, Vaysse N, Susini C (2001) Antiproliferative effect of somatostatin and analogs. Chemotherapy 47 [Suppl 2]: 30–39
Brazeau P, Vale WW, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77–79
Breakman JC, Daloze D, Moussiaux B, Riccio R (1987) Jaspamide from the marine sponge Jaspis Johnstoni. J Nat Prod 50: 994– 995
Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin αvβ3 antagonists promote tumor-regression by inducing apoptosis of angiogenic bloodvessels. Cell 79: 1157–1164
Brown PD (1999) Clinical studies with matrix metalloproteinase inhibitors. APMIS 107: 174–180
Bubb MR, Senderowicz AMJ, Duncan IKK, Korn ED (1994) Jasplakinolide, a cytotoxic natural product induces actin polymerisation and completely inhibits the binding of phalloidin to F-actin. J Biol Chem 269: 14869–14871
Bubb MR, Spector I, Beyer BB, Fosen KM (2000) Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. J Biol Chem 275: 5163– 5170
Buchanan J, Bohacek R, Vu CB, Luke GP (1999a) Preparation of heterocyclic phosphotyrosine derivatives as SH2-mediated signal transduction inhibitors. Patent WO 99 47,529. See Chem Abstr 131: 257875d
Buchanan JL, Bohacek RS, Luke GP, Hatada M, Lu X, Dalgarno DC, Narula SS, Yuan R, Holt DA (1999b) Structrue-based design and synthesis of a novel class of SRC SH2 inhibitors. Bioorg Med Chem Lett 9: 2359–2364
Buchanan JL, Vu CB, Merry TJ, Corpuz EG, Pradeepan SG, Mani UN, Yang M, Plake HR, Varkhedar VM, Lynch BA, MacNeil IA, Loiacono KA, Tiong CL, Holt DA (1999c) Structure-activity relationships of a novel class of SRC SH2 inhibitors. Bioorg Med Chem Lett 9: 2353–2358
Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K,
Scheel-Toellner D, Simmons DL, Akbar AN, Lord JM, Salmon M (1999) RGD peptides induce apoptosis by direct caspase-3 activation. Nature 397: 534–539
Burgess AJ, Pavey S, Warrener R, Hunter L-JK, Piva TJ, Musgrove EA, Saunders N, Parsons PG, Gabrielli BG (2001) Up-regulation of p2WAF/CIP1 by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 60: 828–837
Bürgle M, Koppitz M, Riemer C, König B, Weidle UH, Kellerman J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O, Magdolen V (1997) Inhibition of the interaction of urokinase-type plasminogene activator (uPA) with its receptor (uPAR) synthetic peptides. Biol Chem 378: 231–237
Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Mathur A (2001a) Synthesis of bombesin peptide analogs and their use in treatment of cancer. Patent WO 01 62,777. See Chem Abstr 135: 190403k
Burman AC, Prasad S, Mukherjee R, Singh AT, Mathur A, Gupta N (2001b) Preparation of vasoactive intestinal peptide analogs as anticancer agents. Patent WO 01 60,862. See Chem Abstr 135: 195792w osh AK, HPatent WO 02 10,194. See Chem Abstr 136: 151442y
Butz K, Denk C, Ullman A, Schefner M, Hoppe-Seyler F (2000) Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 97: 6693–6697
Caba JM, Rodriguez IM, Manzanares I, Giralt E, Albericio F (2001) Solid-phase synthesis of trunkamide A J Org Chem 66: 7568– 7574
Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV (1986) Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 83: 1896– 1900
Campbell RM, Scanes CG (1992) Evolution of the growth hormonereleasing factor (GRF) family of peptides. Growth Regul 2: 175– 191
Cao Y, Ji R, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O’Reilly MS, Llinas M, Folkman J (1996) Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271: 29461–29467
Cao Y, Chen A, An SS, Ji RW, Davidson D, Llinas M (1997) Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272: 22924–22928 Cardellini E, Ponti D, Gianfranceschi GL (1999) Phosphorylation of the synthetic octapeptide pyroGlu-ASP-ASP-SER-ASP-GLUGLU- ASN and binding to DNA in presence of divalent cations. Mol Biol Rep 26: 255–259
Cardona C, Rabitts PH, Spindel ER, Ghatei MA, Blehen NM, Bloom SR, Reeve JG (1991) Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res 51: 5205–5211
Carroll AR, Bowden BF, Coll JC, Hockless CR, Skelton BW, White AH (1994) Studies of Australian ascidians. Mollamide, a cytotoxic cyclic heptapeptide from the compound ascidian Didemnum molle. Aust J Chem 47: 61–69
Carroll AR, Coll JC, Bourne DJ, MacLeod JC, Zabriskie TM, Ireland CM, Bowden BF (1996a) Patellins 1–6 and trunkamide A: novel cyclic hexa-, hepta- and octa-peptides from colonial ascidians, Lissoclinum sp. Aust J Chem 49: 659–667
Carroll AR, Feng Y, Bowden BF, Coll JC (1996b) Studies of Australian ascidians 5. Virenamides A–C, new cytotoxic linear peptides from the colonial didemnid ascidian Diplosoma virens. J Org Chem 61: 4059–4061
Carter DC, Moore RE, Mynderse JS, Niemezura WP, Todd JS (1984) Structure of majusculamide C, a cyclic depsipeptide from Lyngbya majuscula. J Org Chem 49: 236–241
Castronovo V, Taraboletti G, Sobel ME (1991) Laminin receptor complementary DNA-deduced synthetic peptide inhibits cancer cell attachment to endothelium. Cancer Res 51: 5672–5678
Chan WR, Tinto WF, Manchand PS, Todaro LJ (1987) Stereostructures of geodiamolides A and B, novel cyclodepsipeptides from the marine sponge Geodia sp. J Org Chem 52: 3091– 3093
Chan KK, Bakhtiar R, Jiang C (1997) Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. Invest New Drugs 15: 195–206
Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH (1998) A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic non small cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer 15: 292–300
Chao DT, Korsmeyer SJ (1998) Bcl-2 family: regulators of cell death. Ann Rev Immunol 16: 395–419
Chen J, Saha P, Kornbluth S, Dynlacht BD, Dutta A (1996) Cyclinbinding motifs are essential for the function of p21Cipl. Mol Cell Biol 16: 4673–4682
Chène P, Fuchs J, Bohn J, García-Echeverría C, Furet P, Fabbro D (2000) A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J Mol Biol 299: 245–253
Chill L, Kashman Y, Schleyer M (1997) Oriamide, a new cytotoxic cyclic peptide containing a novel amino acid from the marine sponge Theonella sp. Tetrahedron 53: 16147–16152
Chillemi F, Lugaro G, Boari D, Cardellini E, Bramucci M, Miano A, Amici D, Gianfranceschi GL, Durban E (1991) Acidic pentapeptide phosphorylated in vitro by calf thymus protein kinase NII binds to DNA in the presence of Mg2+ cations. FEBS Lett 291: 67–70
Clark WD, Corbett T, Valeriote F, Crews P (1997) Cyclocinamide A. An unusual cytotoxic halogenated hexapeptide from the marine sponge Psammocinia. J Am Chem Soc 119: 9285–9286 Cohen B, Colas P, Brent R (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc Natl Acad Sci USA 95: 14272–14277
Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380: 548–550 Coleman JE, de Silva ED, Kong F, Andersen RJ, Allen TM (1995) Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron 51: 10653–10662
Coleman JE, van Soest R, Andersen RJ (1999) New geodiamolides from the sponge Cymbastel sp. collected in Papua New Guinea. J Nat Prod 62: 1137–1141
Coleman PJ, Le TD (2002) Ligands to the integrin receptor αvβ3. Expert Opin Ther Patents 12: 1009–1021
Comoglio P, Ponzetto C (1995) Peptide inhibitors of mitogenesis and motogenesis. Patent WO 9501376. See Chem Abstr 122: 282231n
Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh M, White K, Juiwanna RK, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R (1997) Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest New Drugs 15: 207–218
Corey EJ, Wei-Dong ZL (1999) Total synthesis and biological activity of Lactacystin, Omuralide and analogs. Chem Pharm Bull 47: 1–10
Correia JJ (1991) Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther 52: 127–147
Cosulich SC, Worrall V, Hedge PJ, Green S, Clarke PR (1997) Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol 7: 913–920
Craig WS, Cheng S, Mullen DG, Blevitt J, Pierschbacher MD (1995) Concept and progress in the development of RGD-containing peptide pharmaceuticals. Biopolymers 37: 157–175
Creigthon DJ, Hamilton DS, Kavarana MJ, Sharkey E, Eiseman JL (2000) Glyoxalase enzyme system as a potential target for antitumor drug development. Drugs Future 25: 385–392
Crews P, Manes LV, Boehler M (1986) Jasplakinolide, a cyclodepsipeptide from the marine sponge Jaspis sp. Tetrahedron Lett 27: 2797–2800
Crews P, Farias JJ, Emrich R, Kiefer PA (1994) Milnamide A, an unusual cytotoxic tripeptide from the marine sponge Auletta cf. constricta. J Org Chem 59: 2932–2934
Crul M, de Klerk GJ, Beijnen JH, Schellens JH (2001) Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anti Cancer Drugs 12: 163–184
Cui C-B, Kakeya H, Okada G, Onose R, Ubukata M, Takahashi I, Isono K, Osada H (1995) Tryprostatins A and B, novel mammalian cell cycle inhibitors produced by Apergillus fumigatus. J Antibiot 48: 1382–1384
Cui C-B, Kakeya H, Okada G, Onose R, Osada H (1996a) Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. In taxonomy, fermentation, isolation and biological properties. J Antibiot 49: 527–533
Cui C-B, Kakeya H, Osada H (1996b) Novel mammalian cell cycle inhibitors, tryprostatins A, B and other diketopiperazines produced by Aspergillus fumigatus. II Physio-chemical properties and structures. J Antibiot 49: 534–540
Cui CB, Kakeya H, Osada H (1996c) Novel mammalian cell cycle inhibitors, spirotryprostatins A and B, produced by Aspergillus fumigatus, which inhibit mammalian cell cycle at G2/M phase. Tetrahedron 52: 12651–12666
Cussac D, Vidal M, Leprince C, Liu WQ, Cornille F, Tiraboschi G, Roques BP, Garbay C (1999) A sos-derived peptimer blocks the ras signalling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J 13: 31–38
Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minnna J (1985) Bobesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316: 823–826
D’Souza SE, Ginsberg MH, Plow EF (1991) Arginyl-glycyl-aspartic acid (RGD) a cell adhesion motif. Trends Biochem Sci 16: 246– 250
Daiichi K, Yakuhin KK (1985) Peptide aldehydes. Patent JP 58,164,563. See Chem Abstr 100: 139623g
Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55: 332–338
de Arruda M, Cocchiaro CA, Nelson CM, Grinnell CM, Janssen B, Haupt A, Barlozzari T (1995) LU103793 (NSC D-669356): A synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 55: 3085–3092
De B, Natchus MG, Cheng M, Pikul S, Almstead NG, Taiwo YO, Snider CE, Chen L, Barnett B, Gu F, Dowty M (1999) The next generation of MMP inhibitors: design and synthesis. Ann N Y Acad Sci 878: 40–60
de Castiglione R, Gozzini L (1996) Bombesin receptor antagonists. Crit Rev Oncology-Hematology 24: 117–151
de Silva ED, Andersen RJ, Allen TM (1990) Geodiamolides C to F, new cytotoxic cyclodepsipeptides from the marine sponge Pseudaxnyssa. Tetrahedron Lett 31: 489–492
de Silva ED, Williams dDE, Andersen RJ, Klix H, Holmes CFB, Allen TM (1992) Motuporin, a potent protein phosphatase inhibitor isolated from the Papua New Guinea sponge Theonella swinhoei gray. Tetrahedron Lett 33: 1561–1564
Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemmann AJ, Goodman SL, Kessler H (1999) N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonist. J Med Chem 42: 3033–3040
Degenkolb T, Heinze S, Schlegel B, Dornberger K, Mollmann U, Dahse H-M, Grafe U (2000) Roseoferin, a new aminolipopeptide antibiotic complex from Mycogone rosea DSM 12973, structures and biological activities. J Antibiot 53: 184–190
Delic J, Masdehors P, Ömura S, Cosset J-M, Dumont J, Binet J-L, Magdelénat H (1998) The proteasome inhibitor lactacystin induces apoptosis and snsitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-a-initiated apoptosis. Br J Cancer 77: 1103–1107
Dell A, Williams DH, Morris HR, Smith GA, Feeney J, Roberts CGK (1975) Structure revision of the antibiotics echinomycin. J Am Chem Soc 97: 2497–2502
Diaz JL, Oltersdorf T, Horne W, McConnell M, Wilson G, Weeks S, Garcia T, Fritz LC (1997) A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. J Biol Chem 272: 11350–11355
Draeger LJ, Mullen GP (1994) Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. J Biol Chem 269: 1785– 1793
Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10: 145–155
Duncan SJ, Grüshow S, William DH, McNicholas C, Purawal R, Hajek M, Gerlitz M, Martin S, Wrigley SK, Moore M (2001) Isolation and structure elucidation of chlorofusin a novel p53- MDM2 antagonist from Fusarium sp. J Am Chem Soc 123: 554– 560
Dutta AN (1988a) Luteinizing hormone-releasing hormone (LHRH) agonists. Drugs Future 13: 43–57
Dutta AN (1988b) Luteinizing hormone-releasing hormone (LHRH) antagonists. Drugs Future 13: 761–787
Edler MC, Fernandez AM, Lassota P, Ireland CM, Barrows LR (2002) Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10. Biochem Pharmacol 63: 707–715
Eggen M, Georg GI (2002) The cryptophycins: their synthesis and anticancer activity. Med Res Rev 22: 85–101
Elofson M, Splittgerber U, Myung J, Mohan R, Crews CM (1999) Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α',β'-epoxyketones. Chemistry Biology 6: 811–822
Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long YQ, Roller PP, Yang D, Wang S (2001) Discovery of small-molecule inhibitors of Bcl-2 through structurebased computer screening. J Med Chem 44: 4313–4324
Erba E, Bergamaschi D, Ronzoni S, Faretta M, Taverna S, Bonfati M, Catapano CV, Faircloth G, Jimeno J, D’Incalci M (1999) Mode of action of thiocoraline, a natural marine compound with antitumour activity. Br J Cancer 80: 971–980
Eriksson B, Oberg K (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 10 [Suppl 2]: S31–38
Ettmayer P, France D, Gounarides J, Jarosinski M, Martin M-S, Rondeau J-M, Sabio M, Topiol S, Weidmann M, Zurini M, Bair KW (1999) Structural and conformational requirements for highaffinity binding to the SH2 domain of grb2. J Med Chem 42: 971– 980
Everard MJ, Macaulay VM, Millar JL, Smith IE (1993) [D-Arg1, DPhe5, D-Trp7,9, Leul1] substance P inhibits the growth of human small cell lung cancer xenografts in vivo. Eur J Cancer 29: 1450– 1453
Fabbrizio E, Le Cam L, Polanowska J, Kaczorek M, Lamb N, Brent R, Sardet C (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene 18: 4357–4363
Fåhraeus R, Lain S, Ball KL, Lane DP (1998) Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene 16: 587–596
Fåhraeus R, Paramio JM, Ball KL, Lain S, Lain DP (1996) Inhibition of pRb phosphorylation and cell-cycle progression by a 20- residue peptide derived from p16CDK2/INK4A. Curr Biol 6: 84–91
Fairbrother WJ, Christinger HW, Cochran AG, Fuh G, Keenan CJ, Quan C, Shriver SK, Tom JY, Wells JA, Cunningham BC (1998) Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 37: 17754– 17764
Faulkner DJ (2002) Marine natural products. Nat Prod Rep 19: 1–48 Fazioli F, Blasi F (1994) Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 15: 25–29
Fernández R, Rodríguez J, Quiñoá E, Riguerra R, Muñoz L, Fernández-Suárez M, Debitus C (1996) Onchidin B: a new cyclodepsipeptide from the mollusc Onchidinium sp. J Am Chem Soc 118: 11635–11643
Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG (2001) Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 85: 115–121
Fischer PM, Zhelev NZ, Wang S, Melville JE, Fåhraeus R, Lane DP (2000) Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J Pept Res 55: 163–172
Fisher A, Yang FD, Rubin H, Cooperman BS (1993) R2 C-terminal peptide inhibition of mammalian and yeast ribonucleotide reductase. J Med Chem 36: 3859–3862
Foa P, Chillemi F, Lombardi L, Lonati S, Miaolo AT, Polli EE (1987) Inhibitory activity of synthetic pentapeptide on leukemic myelopoiesis both in vitro and in vivo in rats. Eur J Haematol 39: 399–403
Ford PW, Gustafson KR, McKee TC, Shigematsu N, Maurizi LK, Pannell LK, Williams DE, de Silva ED, Lassota P, Allen TM, van Soest R, Andersen RJ, Boyd MR (1999) Papuamides A-D, HIV-inhibitory and cytotoxic depsipeptides from the sponges Theonella mirabilis and Theonella swinhoei collected in Papua New Guinea. J Am Chem Soc 121: 5899–5909
Foster BA, Coffey HA, Morin MJ, Rastinjad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507–2510
Frankenne F, Noel A, Bajou K, Sounni NE, Goffin F, Mason V, Munaut C, Remacle A, Froidart JM (1999) Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. Emerging Ther Targets 3: 469–481
Fretz H, Furet P, García-Echeverría C, Rahuel J, Schoepfer J (2000) Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways. Curr Pharm Des 6: 1777–1796
Fujisawa N, Hayashi S, Miller EJ (1999) A synthetic peptide inhibitor for alpha-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice. Melanoma Res 9: 105–114
Fukuda MN, Ohvama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslati E, Fukuda M (2000) A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonisation of tumor cells. Cancer Res 60: 450–456
Furuta T, Hayashi H (1986) Antitumor protein isolation from human cell line. Patent JP 60,226,816. See Chem Abstr 104: 180205t
Fusetani N, Sugawara T, Matsunaga S, Hirota H (1991) Orbiculamide A: a novel cytotoxic cyclic peptide from a marine sponge Theonella sp. J Am Chem Soc 113: 7811–7812
Gademann K, Kimmerlin T, Hoyer D, Seebach D (2001) Peptide folding induces high and selective affinity of a linear and small β- peptide to the human somatostatin receptor. J Med Chem 44: 2460–2468
Gademann K, Seebach D (2001) Synthesis of cyclo-β-tripeptides and their biologial in vitro evaluation as antiproliferative against the growth of human cancer cell lines. Helv Chim Acta 84: 2924– 2937
Galvez AF (2002) Therapeutic peptides having a motif that binds specifically to nonacetylated H3 and H4 histones for cancer therapy. Patent WO 01 72,784. See Chem Abstr 135: 283175c
Galvez AF, Chen N, Macsaieb J, de Lumen BO (2001) Chemopreventive property of a soybean peptide (lunasin) that binds to deacetylated histones and inhibits their acetylation. Cancer Res 61: 7473–7478
Gamble WR, Durso NA, Fuller RW, Westergaard CK, Johnson TR, Sackett DL, Hamel E, Cardellina JH, Boyd MR (1999) Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem 7: 1611–1615
Garbay C, Liu W-Q, Vidal M, Roques BP (2000) Inhibitors of RAS signal transduction as antitumor agents. Biochem Pharmacol 60: 1165–1169
García-Echeverría C, Chène P, Blommers MJJ, Furet P (2000) Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J Med Chem 43: 3205–3208
Gaudron S, Grillon C, Thierry J, Riches A, Wierenga PK, Wdzieczak-Bakala J (1999) In vitro effect of acetyl-N-Ser-Asp- Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation. Stem Cells 17: 100–106
Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J (1999) Selective GRB2 SH2 inhibitors as anti-ras therapy. Int J Cancer 83: 235–241
Gazal S, Gelerman G, Ziv O, Karpov O, Litman P, Bracha M, Afargan M, Gilon C (2002) Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units. J Med Chem 45: 1665–1671
Gazos Lopes U, Erhardt P, Yao R, Cooper GM (1997) p53- dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893–12896
Ge R, Kini RM (2001) Small peptides having potent anti-angiogenic activity. Patent WO 01 18,030. See Chem Abstr 134: 217187m Gembistky DS, De Angelis PM, Reichelt KL, Elgjo K (2000) An endogenous melanocyte-inhibiting tripeptide pyroGlu-Phe- GlyNH2 delays in vivo growth of monoclonal experimental melanoma. Cell Proliferation 33: 91–99
Georg GI, Ali SM, Stella VJ, Waugh WN, Himes RH (1998) Halohydrin analogues of cryptophycin 1: synthesis and biological activity. Bioorg Med Chem Lett 8: 1959–1962
Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T (2000) p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2: 709– 717
Gilmer T, Rodriguez M, Jordan S, Crosby R, Alligood K, Green M, Kimery M, Wagner C, Kinder D, Charifson P, Hassel AM, Willard D, Luther M, Rusnak D, Sternbach DD, Mehrotra M, Peel M, Burkhart W, Moyer M, Brdshaw T, Berman J (1994) Peptide inhibitors of src SH3-SH2-phosphoprotein interaction. J Biol Chem 269: 31711–31719
Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancuso T, Bagansco L, Russo P, Parodi S (1998) Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequnce. Cancer Res 58: 3654–3659
Goetz G, Yoshida WY, Scheuer PJ (1999) The absolute stereochemistry of Kahalalide F. Tetrahedron 55: 7739–7746
Goldberg J, Huang H, Kwon Y, Greengard P, Nairn AC, Kuriyan J (1995) Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376: 745– 753
Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S (1994) Highaffinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 91: 7129– 7133
Gradishar WJ, Vogelzang NJ, Kilton LJ, Leibach SJ, Rademaker AW, French S, Benson AB (1995) A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. Invest New Drugs 13: 171–174
Gräfe U, Schlegel R, Ritzau M, Ihn W, Dornberger K, Stengel C, Fleck WF, Gitsche W, Härtl A, Paulus EF (1995) Aurantimycins, new depsipeptide antibiotics from Streptomyces aurantiacus IMET 43917 production, isolation, structure elucidation, and biological activity. J Antibiot 48: 119–125
Graz CJ, Grant GD, Brauns SC, Hunt A, Jamie H, Milne PJ (2000) Cyclic dipeptides in the induction of maturation for cancer therapy. J Pharm Pharmacol 52: 75–82
Grieco PA, Reilly M (1998) Studies related to the absolute configuration of cyclocinanmide A: total synthesis of 4(R),11(R)- cyclocinamide. Tetrahedron Lett 39: 8925–8928
Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899– 1911
Gulavita NK, Gunasekera SA, Pomponi SA, Robinson EV (1992) Polydiscamde A: a new bioactive depsipeptide from the marine sponge Discodermia sp. J Org Chem 57: 1767–1772
Guo NH, Krutzsch HC, Inman JK, Shannon CS, Roberts DD (1997) Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. J Pept Res 50: 210–221
Guo Y, Higazi AA-R, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA (2000) A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14: 1400–1410
Halazonetis T, Hartwig W (1996) Peptides and peptidomimetics which activate human p53 DNA binding and their use as therapeutics. Patent WO 96 25,434. See Chem Abstr 125: 257158y
Halazonetis T, Hartwig W (2001) Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function. Patent US 6,245,886. See Chem Abstr 135: 51039h
Hall I, Chen SY (1999) Substituted 4-hydroxyproline di- and tripeptides as cytotoxic agents. Amino Acids 16: 79–89
Hamann MT, Scheuer PJ (1993) Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J Am Chem Soc 115: 5825–5826
Hamel E (1992) Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatin 10 and 12 and halichondrin B. Pharmacol Ther 55: 31–51
Han DC, Shen TL, Guan JL (2001) The Grb7 family proteins: structure, interactions with other signalling molecules and potential cellular functions. Oncogene 20: 6315–6321
Hao Y, Zhang R, Li C, Xu X (1995) Design and synthesis of antibacterial and antitumor peptides containing a SPXX motif. Beijing Daxue Xuebao, Ziran Kexueban 31: 703–710 See Chem Abstr 124: 331693s
Harrigan GG, Harrigan BL, Davidson BS (1997) Kailuins A-D, new cyclic acyldepsipeptides from cultures of a marine-derived bacterium. Tetrahedron 53: 1577–1582
Harrigan GG, Yoshida WY, Moore RE, Nagle DG, Park PU, Biggs J, Paul VJ, Mooberry SL, Corbett TH, Valeriote FA (1998) Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula / Schizothrix calcicola cyanobacterial assemblages. J Nat Prod 61: 1221–1225
Harrigan GG, Luesch H, Yoshida WY, Moore RE, Nagle DG, Paul VJ (1999) Symplostatin 2: a dolastatin 13 analogue from marine cyanobacterium Symploca hydnoides. J Nat Prod 62: 655–658
Hart CP, Martin JE, Reed MA, Keval AA, Pustelnik MJ, Northrop JP, Patel VD, Grove JR (1999) Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries. Cell Signal 11: 453–464
Haubner R, Finsinger D, Kessler H (1997) Stereoisomeric peptides libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed Engl 36: 1375–1389
Haviv F, Henkin J, Bradley MF, Kalvin DM (2001a) Preparation of N-alkylated peptides having antiangiogenic activity. Patent WO 01 38,397. See Chem Abstr 135: 5822k
Haviv F, Henkin J, Bradley MF, Kalvin DM, Schneider AJ (2001b) Preparation of peptides having antiangiogenic activity. Patent WO 01 38,347. See Chem Abstr 135: 5821j
Hawkins CJ, Lavin MF, Marshall KA, van den Brenk AL, Watters DJ (1990) Structure-activity relationships of the lissoclinamides: cytotoxic cyclic peptides from the ascidian Lissoclinum patella. J Med Chem 33: 1634–1638
Hayakawa Y, Adachi H, Kim JW, Shin-Ya K, Seto H (1998) Adenopeptin, a new apoptosis inducer in transformed cells from Chrysosporium sp. Tetrahedron 54: 15871–15878
Hayashi S, Kurdowska A, Cohen AB, Stevens MD, Fujisawa N, Miller EJ (1997) A synthetic peptide inhibitor for alphachemokines inhibits the growth of melanoma cell lines. J Clin Invest 99: 2581–2587
Hayashi Y, Orikasa S, Tanaka K, Kanoh K, Kiso Y (2000) Total synthesis of anti-microtubule diketopiperazine derivatives: Phenylahistin and aurantiamine. J Org Chem 65: 8402–8405
Heasley LE (2001) Autocrine and paracrine signalling through neuropeptide receptors in human cancer. Oncogene 20: 1563–1569
Helbecque N, Bernier JL, Hénichart JP (1985) Design of a new DNA-polyintercalating drug, a bisacridinyl peptidic analogue of triostin A. Biochem J 225: 829–832
Helmreich EJM (2001) The biochemistry of cell signalling. New York, Oxford University Press
Heppeler A, Froidevaux S, Eberle AN, Maecke HR (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7: 971–994
Hirota A, Suzuki A, Aizawa K, Tamura S (1973) Structure of cyl-2, a novel cyclotetrapeptide from Cylindrocladium scoparium. Agric Biol Chem 37: 955–956
Hitotsuyanagi Y, Anazawa Y, Yamagishi T, Samata K, Ichihara T, Nanaumi K, Okado N, Nakaike S, Mizumura M, Takeya K, Itokawa H (1997) Novel water-soluble analogues retaining potent antitumor activity of RA-VII, a cyclic hexapeptide from Rubia plants. Bioorg Med Chem Lett 7: 3125–3128
Hiwasa T, Soeda C, Takanohashi S, Kobayashi H, Suzuki A, Ueyama T, Ike Y (1996) Screening of peptides which suppress the proliferation of transformed cells. Int J Oncol 8: 125–129 Hocart SJ, Jain R, Murphy WA, Taylor JE, Coy DH (1999) Highly potent cyclic disulfide antagonist of somatostatin. J Med Chem 42: 1863–1871
Hochster H, Oratz R, Ettinger DS, Borden E (1999) A phase II study of didemnin B (NSC 325319) in advanced malignant melanoma: an eastern cooperative oncology group study (PB687). Invest New Drugs 16: 259–263
Hoffken K, Kath R (2000) Peptides in Oncology III: Somatostatin and LH-RH analogues. Springer, Berlin Heidelberg New York Tokyo
Hoefle G, Leibold T, Steinmetz H (2002) Preparation of stereospecific synthetic tubulysins and intermediate. Patent DE 10,008,089. See Chem Abstr 135: 331296s
Holinger EP, Chittenden T, Lutz RJ (1999) Bak BH3 peptides antagonize Bcl-XL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 274: 13298–13304
Hollstein V (1974) Actionmycin. Chemistry and mechanism of action. Chem Rev 74: 625–652
Hozumi M, Ogawa M, Sugimura T, Takeuchi T, Umezawa H (1972) Inhibition of tumorigenesis in mouse skin by leupeptin, a protease inhibitor from Actinomycetes. Cancer Res 32: 1725–1728
Huang Z (2000) Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19: 6627–6631
Huang Z, Lui D, Han X, Zhang Z, Wang J (2000) Small molecule inhibitors of Bcl-2 proteins for inducing apoptosis. Patent WO 00 04,901. See Chem Abstr 132: 117566z
Huber HE, Koblan KS, Heimbrook DC (1994) Protein-protein interactions as therapeutic targets for cancer. Curr Med Chem 1: 13–34
Huirne JA, Lambalk CB (2001) Gonadotropin-releasing-hormonereceptor antagonists. Lancet 358: 1793–1803
Humphries MJ, Olden K, Yamada KM (1986) A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233: 467–470
Hupp TR, Lane DP, Ball KL (2000) Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 352: 1– 17
Hynes RO (1992) Integrins: versatility, modulation, and signalling in cell adhesion. Cell 69: 11–25
Ijaz T, Tran P, Ruparelia KC, Teesdale-Spittle PH, Orr S, Patterson LH (2001) Anthraquinonepeptides as inhibitors of AP-1 transcription factor. Bioorg Med Chem Lett 11: 351–353
Ike Y, Kobayashi A, Suzuki A, Hiwasa S (1997) Antitumor agents containing tripeptides or dipeptides. Patent JP 09,40,577. See Chem Abstr 126: 233697t
Ikegami S, Miyashiro S, Saki T, Shibai H (1987) Manufacture of antitumor polypeptides. Patent JP 61,93,125. See Chem Abstr 106: 31371h
Ireland CM, Durso AR, Newman RA, Hacker MP (1982) Antineoplastic cyclic peptides from the marine tunicate Lissoclinum patella. J Org Chem 47: 1807–1811
Ishida K, Nakagawa H, Murakami M (2000) Microcyclamide, a cytotoxic cyclic hexapeptide from the cyanobacterium Microcystis aeruginosa. J Nat Prod 63: 1315–1317
Ishiwata H, Nemoto T, Ojika M, Yamada K (1994a) Isolation and stereostructure of doliculide, a cytotoxic cyclodepsipeptide from the Japanese sea hare Dolabella auricularia. J Org Chem 59: 4710–4711
Ishiwata H, Sone H, Kigoshi H, Yamada K (1994b) Enantioselective total synthesis of doliculide a potent cytotoxic cyclodepsipeptide of marine origin and structure-cytotoxicity relationships of synthetic doliculide congeners. Tetrahedron 50: 12853–12882
Ishiwata H, Sone H, Kigoshi H, Yamada Y (1994c) Total synthesis of doliculide, a potent cytotoxic cyclodepsipeptide from the Japanese sea hare Dolabella auricularia. J Org Chem 59: 4712– 4713
Isoai A, Giga-Hama Y, Shinkai K, Mukai M, Akedo H, Kumagai H (1992) Tumor invasion-inhibiting factor 2: primary structure and inhibitory effect on invasion in vitro and pulmonary metastasis of tumor cells. Cancer Res 52: 1422–1426
Itagaki F, Shigemori H, Ishibashi M, Nakamura T, Sasaki T, Kobayashi J (1992) Keramamide F, a new thiazole-containing peptide from the okinawan marine sponge Theonella sp. J Org Chem 57: 5540–5542
Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai I, Terui A, Yoshimatsu S, Ikenishi Y, Nakagawa Y (1990) Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot 43: 1524–1532
Itokawa H, Takeya K (1993) Antitumor substances from higher plants. Heterocycles 35: 1467–1487
Iwamoto Y, Robey FA, Graf J, Saski M, Kleinman HK, Yamada Y, Martin GR (1987) YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238: 1132– 1134
Jacob L, Zasloff M (1994) Potential therapeutic applications of magainins and other microbial agents of animal origin. Ciba Foundation Symposium 186: 197–223
Janssen B, Barlozzari T, Haupt A, Zierke T, Kling A (1998) Preparation of dolastatin 15 derivatives as antitumor agents. Patent WO 99 03,879. See Chem Abstr 130: 139656q
Jensen PKA, Elgjo K, Laerum OD, Bolund L (1990) Synthetic epidermal pentapeptide and related growth regulatory peptides inhibit proliferation and enhance differentiation in primary and regenerating cultures of human epidermal keratinocytes. J Cell Sci 97: 51–58
Jia H, Jezequel S, Lohr M, Shaikh S, Davis D, Soker S, Selwood D, Zachary I (2001) Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF. Biochem Biophys Res Commun 283: 164–173
Jiang TL, Liu RH, Salmon SE (1983) Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11: 1–4
Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, Rivier JE (2001) GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 44: 453–467
Jimeno JM (2002) A clinical armamentarium of marine-derived anti-cancer compounds. Anti-Cancer Drugs 13: S15–S19
Johnson LL, Dyer R, Hupe DJ (1998) Matrix metalloproteinases. Curr Opin Chem Biol 2: 466–471
Jordan MA, Wilson L (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123–130
Jordan MA, Walker D, De Arruda M, Barlozzari T, Panda D (1998) Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry 37: 17571–17578
Jouin P, Poncet J, Dufour M-N, Aumelas A, Pantaloni A, Cros S, François G (1991) Antineoplastic activity of didemnin congeners: nordidemnin and modified chain analogues. J Med Chem 34: 486– 491
Kaiser M, Groll M, Renner C, Huber R, Moroder L (2002) The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew Chem Int Ed 41: 780–783
Kamenecka TM, Danishefsky SJ (1998) Total synthesis of himastatin: confirmation of the revised stereostructure. Angew Chem Int Ed Engl 37: 2995–2998
Kaneda Y, Yamamoto Y, Okada N, Tsutsumi Y, Nakagawa S, Kakiuch M, Maeda M, Kawasaki K, Mayumi T (1997) Antimetastatic effect of synthetic Glu-Ile-Leu-Asp-Val peptide derivatives containing D-amino acids. Anti-Cancer Drugs 8: 702– 707
Kanoh K, Kohno S, Katada J, Hayashi Y, Muramaytsu M, Uno I (1999a) Antitumor activity of phenylahistin in vitro and in vivo. Biosci Biotechnol Biochem 63: 1130–1133
Kanoh K, Kohno S, Katada J, Takahashi J, Uno I (1999b) (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. J Antibiot 52: 134–141
Kanoh K, Kohno S, Katada J, Takahashi J, Uno I, Hayashi Y (1999c) Synthesis and biological activities of phenylhistin derivatives. Bioorg Med Chem 7: 1451–1457
Kardinal C, Konkol B, Schulz A, Posern G, Lin H, Adermann K, Eulitz M, Estrov Z, Talpaz M, Arlinghaus RB, Feller SM (2000) Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J 14: 1529– 1538
Kavarana MJ, Kovaleva EG, Creighton DJ, Wollman MB, Eiseman JL (1999) Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities and stabilities in human serum and mouse serum. J Med Chem 42: 221–228
Kawasaki K, Maeda M, Inoue S, Yamashiro Y, Kaneda Y, Mu Y, Tsutsumi Y, Nakagawa S, Mayumi T (1996) Amino acids and peptides. XXIX. Synthesis and antimetastatic effects of peptides and peptide-poly(ethylene glycol) hybrids related to the core sequence of the type III connecting segment domain of fibronectin. Biol Pharm Bull 19: 1574–1579
Keller-Schierlein W, Mihailovic ML, Prelog V (1959) Stoffwechselprodukte von Actinomyceten. Helv Chem Acta 42: 305–322
Kéri G, Mezô I, Vadsáz Z, Horváth A, Idei M, Vántus T, Balogh A, Bökönyi G, Bajor T, Teplan I, Tamás J, Mák M, Horváth J, Csuka O (1993) Structure-activity relationship studies of novel somatostatin analogs with antitumor activity. Pept Res 6: 281–288
Khachigian LM, Field SL, Crouch R, Chesterman CN (1995) Platelet-derived factor A-chain synthetic peptide inhibits human glioma xenograft proliferation in nude mice. Anticancer Res 15: 337–341
Khavinson VK, Anisimov VN (2000) Synthetic pineal peptide increase a life span and inhibits a development of tumors in mice. Dokl. Akad. Nauk. 373: 567–569. See Chem Abstr 134: 95241b
Khiat A, Lamoureux M, Boulanger Y (1996) Structural differences between the free and bound states of the DNA-bisintercalating peptide YSPTSPSY J Med Chem 39: 2492–2498
Kiaris H, Schally AV, Sun B, Armatis P, Groot K (1999) Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene 18: 7168–7173
Kijima J, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993) Trapoxin, an antitumor cyclic tetrapeptide is an irreversible inhibitors of mammalian histone deacetylase. J Biol Chem 268: 22429–22435
Kim SE, Kim HH, J.Y. K, Kang YI, Woo HJ, Lee HJ (2000) Anticancer activity of hydrophobic peptides from soy proteins. BioFactors 12: 151–155
Kim SS, Kim YH, Park MG, Park EG, Yeo UH, Lee SC, Lee YH, Chae SY (2002) Novel peptidyl antibiotic produced from ascomycetes Apiocra sp. 14t strain, preparation method and use thereof. Patent KR 2000 56,350. See Chem Abstr 136: 324169v
Kineman RD (2000) Antitumorigenic actions of growth hormonereleasing hormone antagonists. Proc Natl Acad Sci USA 97: 532– 534
Kini RM, Evans HJ (1995) A hypothetical structural role for proline residues in the flanking segments of protein-protein interaction sites. Biochem Biophys Res Commun 212: 1115–1124
Kitagawa I, Kobayashi S (1996) Isolation of arenastatin A having antitumor activity from Dysidea arenaria marine sponge and its total synthesis. patent JP 08,92,232. See Chem Abstr 125: 115144s
Kobayashi H, Ohi H, Shinohara H, Sugimura M, Fujii T, Terao T, Schmitt M, Goretzki L, Chocholowski N, Jänicke F, Graeff H (1993) Saturation of tumor cell surface receptors for urokinasetype plasminogen activator by amino-terminal fragment of and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 67: 537–544
Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T (1994a) Inhibition of metastasis of lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis mode. Int J Cancer 57: 727–733
Kobayashi M, Kurosu M, Ohyabu N, Wang W, Fujii S, Kitagawa I (1994b) The absolute stereostructure of arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria. Chem Pharm Bull 42: 2196–2198
Kobayashi M, Wang W, Ohyabu N, Kurosu M, Kitagawa I (1995) Improved total synthesis and structure-activity relationship of arenastatin A, a potent cytotoxic spongean depsipeptide. Chem Pharm Bull 43: 1598–1600
Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyasaki K, Gondo M, Sakakibara K, Tsukagoshi S (1997) Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316–327
Kobayashi J, Suzuki H, Shimbo K, Takeya K, Morita H (2001) Celogentins A-C, new antimitotics bicyclic peptides from the seeds of Celosia argentea. J Org Chem 66: 6626–6633
Koehn FE, Longley RE, Reed JK (1992) Microcolins A and B, new immunosuppressive peptides from the blue-green alga Lyngbya majuscula. J Nat Prod 55: 613–619
Koguchi Y, Nishio M, Suzuki S-I, Takahashi K, Ohnuki T, Komatsubara S (2000) TMC-89A and B, new proteasome inhibitors from Streptomyces sp. TC 1087. J Antibiot 53: 967– 972
Kohda K, Ohta Y, Yokoyama Y, Kawazoe Y, Kato T, Suzumura Y, Hamada Y, Shioiri T (1989) Mechanistic aspects of the cytocidal action of ulithiacyclamide on mouse leukemia L1210 cells in vitro. Biochem Pharmacol 38: 4497–4500
Kohen F, Natarajan V, Kasher R, Fridkin M, Katchalskikatzir E (2002) Peptides mimicking the biological activity of steroids hormones, and their therapeutic uses. Patent WO 01 74,846. See Chem Abstr 135: 283229y
Kohno J, Koguchi Y, Nishio M, Nakao K, Kuroda M, Shimizu R, Ohnuki T, Komatsubara S (2000) Structure of TMC-95A-D: novel proteasome inhibitors form Apiospora montagnei Sacc. TC 1093. J Org Chem 65: 990–995
Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg C, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17: 768–774
Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H (2001) Cyclic hydroxamic-acid-containing petide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res 61: 4459–4466
Konishi M, Ohkuma H, Sakai F, Tsuno T, Koshiyama H, Naito T, Kawagushi H (1981) BBM-928, a new antitumor antibiotic complex III. Structure determination of BBM-928 A, B and C. J Antibiot 34: 148–159
Kouzarides T (1998) Method and means for disruption of p53 and RB interaction. Patent WO 97 41,433. See Chem Abstr 128: 18684x
Krulich L, Dhariwal APS, McCann SM (1968) Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from pituitary in vitro. Endocrinology 83: 783– 790
Kutscher B, Bernd M, Beckers T, Polymeropoulos EE, Engel J (1997) Chemistry and molecular biology in the search for new LHRH antagonists. Angew. Chem Int Ed Engl 36: 2149–2161
Kwekkeboom D, Krenning EP, de Jong M (2000) Peptide receptor imaging and therapy. J Nucl Med 41: 1704–1713
Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97: 290–296
Lacey E, Edgar JA, Culvenor CCJ (1987) Interaction of phomopsin A and related compounds with purified sheep brain tubulin. Biochem Pharmacol 36: 2133–2138
Laerum OD (1990) Preparation of pentapeptides and derivatives as stem cell proliferation inhibitors. Patent EP 359,338. See Chem Abstr 113: 115878m
Lam KS, Gustavson DR, Hesler GA, Dabrah TT, Matson JA, Berry RL, Rose WC, Forenza S (1995) Korkormicins, novel depsipeptide antitumor antibiotics from Micromonospora sp C39500: fermentation, precursor directed biosynthesis and biological activities. J Ind Microbiol 15: 60–65
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. New England J Med 334: 246–254
Lane DP, Hall PA (1997) MDM2-arbiter of p53’s destruction. Trends Biochem Sci 22: 372–374
Langdon S, Sethi T, Ritchie A, Muir M, Smyth J, Rozengurt E (1992) Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 52: 4554– 4557
Larsen IK (1996) A Textbook of Drug Design and Development. In: Krogsgaard-Larsen P, Liljefors T, Madsen U (eds) A Textbook of drug design and development. Harwood Academic, pp 460– 506
Lenfant M, Wdzieczak-Balaka J, Guittet E, Prome JC, Sotty D, Fringel E (1989) Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 86: 779–782
Leonard DM, Sebolt-Leopold JS (1999) Ras farnesyltransferase inhibitors. Drugs Future 24: 1099–1106
Leung D, Abbenante G, Fairlie DP (2000) Protease inhibitors: current status and future prospect. J Med Chem 43: 305– 341
Leyton J, Coelho T, Coy DH, Jakowlew S, Birrer MJ, Moody TW (1998) PACAP(6–38) inhibits the growth of prostate cancer cells. Cancer Lett 125: 131–139
Li H, Matsunaga S, Fusetani N (1995a) Halicylindramides A-C, antifungal and cytotoxic depsipeptides from the marine sponge Halichondria cylindrata. J Med Chem 38: 338–343
Li Y, Koiso Y, Kobayashi H, Hashimoto Y, Iwasaki S (1995b) Ustiloxins, new antimitotic cyclic peptides: interaction with porcine brain tubulin. Biochem Pharmacol 49: 1367–1372
Li H, Matsunaga S, Fusetani N (1996) Halicylindramides D and E, antifungal peptides from the marine sponge Halichondria cylindrata. J Nat Prod 59: 163–166
Liakopoulou-Kyriakides M, Stavropoulos G, Geromichalos G, Papazisis KT, Kortsaris AH, Kyriakidis DA (1998) Antiproliferative activity of synthetic tetrapeptides, analogs of AS-I phytotoxin, towards cancer cell lines. Anti-Cancer Drugs 9: 175– 179
Liehr S, Barbosa J, Smith AB, Cooperman BS (1999) Synthesis and biological activity of cyclic peptide inhibitors of ribonucleotide reductase. Org Lett 1: 1201–1204
Liesch JM, Sweeley CC, Staffeld GD, Anderson MS, Weber DJ, Scheffer RP (1982) Structure of HC-toxin, a cyclic tetrapeptide from Helminthosporum carbonum. Tetrahedron 38: 45–48
Lin JT, Coy DH, Mantey SA, Jensen RT (1995) Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors. Eur J Pharmacol 294: 55–69
Lingham RB, Hsu AHM, O’Brien JA, Sigmund JM, Sanchez M, Gagliardi MM, Heimbuch BK, Genilloud O, Martin I, Diez MT, Hirsch CF, Zink DL, Liesch JM, Koch GE, Garter SE, Garrity GM, Tsou NN, Salituro GM (1996) Quinoxapeptins: Novel chromodepsipeptide inhibitors of HIV-1 and HIV-2 reverse transcriptase. J Antibiot. 49: 253–259
Liu D-G, Yao Z-J, Gao Y, Burke TR (2000a) Large scale preparation of cell permeable nonphosphate-containing Grb2 SH2 domain inhibitors. Org Prep Proced Int 32: 197–201
Liu W-Q, vidal M, Mathé C, Périgaud C, Garbay C (2000b) Inhibition of the ras-dependant mitogenic pathway by phosphopeptide prodrugs with antiproliferative properties. Bioorg Med Chem Lett 10: 669–672
Liu Y, Elgjo K, Wright M, Reichelt KL (2000c) Novel lymphocyte growth-inhibiting tripeptide: N-acetyl-Glu-Ser-Gly-NH2. Biochem Biophys Res Commun 277: 562–567
Loffet A (2002) Peptides as drugs: is there a market? J Pept Sci 8: 1–7
Long Y-Q, Voigt JH, Lung F-D, King CR, Roller PP (1999) Significant compensatory role of position Y-2 conferring high affinity to non-phosphorylated inhibitors of GRB2-SH2 domain. Bioorg Med Chem Lett 9: 2267–2272
López-Macià A, Jiménez JC, Royo M, Giralt E, Albericio F (2001) Synthesis and structure determination of kahalalide F (1,2). J Am Chem Soc 123: 11398–11401
Ludueña RF, Roach MC, Prasad V, Banerjee M, Koiso Y, Li Y, Iwasaki S (1994) Interaction of ustiloxin A with bovine brain tubulin. Biochem Pharmacol 47: 1593–1599
Luesch H, Yoshida WY, Moore RE, Paul VJ (1999) Lyngbyastatin 2 and norlungbyastatin 2, analogues of Dolastatin G and nordolastatin G from the marine cyanobacterium Lyngbya majuscula. J Nat Prod 62: 1702–1706
Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH (2001a) Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod 64: 907–910
Luesch H, Pangilinan R, Yoshida WY, Moore RE, Paul VJ (2001b) Pitipeptolides A and B, new cyclodepsipeptides from the marine cyanobacterium Lyngya majuscula. J Nat Prod 64: 304– 307
Luesch H, Yoshida WY, Moore RE, Paul VJ, Corbett TH (2001c) Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc 123: 5418–5423
Luesch H, Yoshida WY, Moore RE, Paul VJ (2002) New apratoxins of marine cyanobacterial origin from Guam and Palau. Bioorg Med Chem 10: 1973–1978
Luke RWA, Hudson K, Hayward CF, Fiedling C, Cotton R, Best R, Giles MB, Veldman MH, Griffiths LA, Jewsbury PJ, Breeze AL, Embrey KJ (1999) Design and synthesis of small molecule inhibitors of the MDM2-p53 interaction as potential anti-tumor agents. Proc Am Assoc Cancer Res 40: 622
Lung FD, Long YQ, Roller PP, King CR, Varady J, Wu XW, Wang S (2001) Functional preference of the constituent amino acid residues in a phage-library-based nonphosphorylated inhititor of the Grb2-SH2 domain. J Pept Res 57: 447–454
Lunney EA, Para KS, Rubin JR, Humblet C, Fergus JH, Marks JS, Sawyer TK (1997) Structure-based design of a novel series of nonpeptide ligands that bind to the pp60src SH2 domain. J Am Chem Soc 119: 12471–12476
Lupu R, Lippman M (1994) Peptides that bind ligands of the epidermal growth factor receptor and erbB-2-receptor. Patent WO 93 22,339. See Chem Abstr 120: 209532r
Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, Willard D, Luther M, Rodriguez M, Berman J, Gilmer TM (1994) Involvement of pp60c-src with two major signalling pathways in human breast cancer. Proc Natl Acad Sci USA 91: 83–87
Madden T, Tran HT, Beck D, Huies R, Newman RA, Pusztai L, Wright JJ, Abbruzzeses JL (2000) Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res 6: 1293–1301
Maehr H, Liu C, Palleroni NJ, Smallheer J, Todaro L, Williams TH, Blount JF (1986) Microbial Products VIII. Azinothricin, a novel hexadepsipeptide antibiotic. J Antibiot 39: 17–25
Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R (2001) Extracellular matrix-derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem 276: 31959–31968
Magnifico A, Tagliabue E, Butó S, Ardini E, Castronovo V, Colnaghi MI, Ménard S (1996) Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells. J Biol Chem 271: 31179–31184
Maini A, Morse PD, Wang CY, Jones RF, Haas GP (1997) New developments in the use of cytokines for cancer therapy. Anticancer Res 17: 3803–3808
Mamber SW, Brookshire KW, Dean BJ, Firestone RA, Leet JE, Matson JA, Forenza S (1994) Inhibition of antibacterial activity of himastatin, a new antitumor antibiotic from Streptomyces hygroscopicus by fatty acid sodium salts. Antimicrob Agents Chemother 38: 2633–2642
Manderville RA, Ellena JF, Hecht SM (1994) Solution structure of a Zn(II)-bleomycin A5-d(CGCTAGCG)2 complex. J Am Chem Soc 116: 10851–10852
Maroun JA, Stewart D, Verma S, Eisenhauer E (1998) Phase I clinical study of didemnin B. Invest New Drugs 16: 51–56
Marsili V, Nardicchi V, Lupidi G, Brozzetti A, Gianfranceschi GL (1996) Dansylated octapeptide Dns-Glu-Asp-Asp-Ser-Asp-Glu- Glu-Asn inhibits the proliferation rate of HL-60 cells. Can J Physiol Pharmacol 74: 1302–1307
Martin DG, Mizsak SA, Biles C, Stewart JC, Baczynskyj L, Meulman PA (1975) Structure of quinomycin antibiotics. J Antibiot 28: 332–336
Martin GR, Sasaki M, Yamada Y, Kleinman HK, Robey F, Iwamoto Y, Graf JO (1989) Peptides with laminin activity. Patent EP 278,781. See Chem Abstr 111: 109027a
Masuoka Y, Shin-Ya K, Kim YB, Yoshida M, Nagai K, Suzuki K-I, Hayakawa Y, Seto H (2000) Diheteropeptin, a new substance with TGF-β-like activity, produced by a fungus, Diheterospora chlamydosporia. Part 1. Production, Isolation and biological activities. J Antibiot 53: 788–792
Masuoka Y, Nagai A, Shin-Ya K, Furihata K, Nagai K, Suzuki KI, Hayakawa Y, Seto H (2001) Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tetrahedron Lett 42: 41–44
Matson JA, Bush JA (1989) Sandramycin, a novel antitumor antibiotic produced by a Nocardioides sp. J Antibiot 42: 1763– 1767
Matson JA, Colson KL, Belofsky GN, Bleiberg BB (1993) Sandramycin, a novel antitumor antibiotic produced by a Nocardioides sp. II. Structure determination. J Antibiot 46: 162– 166
Matsuda M, Asakura S, Myuuraa EU (1996) Cell adhesion inhibitory peptides derived from human high-molecular-weight kininogen L-chain. Patent JP 08,208,692. See Chem Abstr 125: 276595e
Matsumoto Y, Kawatani M, Simizu S, Tanaka T, Takada M, Imoto M (2000) Bcl-2-independent induction of apoptosis by neuropeptide receptor antagonist in human small cell lung carcinoma cells. Anticancer Res 20: 3123–3129
Matsunaga S, Fusetani N (1995) Theonellamides A-E, cytotoxic bicyclic peptides, from a marine sponge Theonella sp. J Org Chem 60: 1177–1181
Matsunaga S, Fusetani N, Konosu S (1984) Bioactive marine metabolites VI. Structure elucidation of discodermin A, an antimicrobial peptide from the marine sponge Discodermia kiiensis. Tetrahedron Lett 25: 5165–5168
Matsunaga S, Fusetani N, Konosu S (1985a) Bioactive marine metabolites VII. Structures of discodermins B, C and D antimicrobial peptides from the marine sponge Discodermia kiiensis. Tetrahedron Lett 26: 855–856
Matsunaga S, Fusetani N, Konosu S (1985b) Bioactive marine metabolites IV. Isolation and the amino acid composition of discodermin A, an antimicrobial peptide, from the marine sponge Discodermia kiiensis. J Nat Prod 48: 236–241
Mattock H, Lane DP, Warbrick E (2001) Inhibition of cell proliferation by the PCNA-binding region of p21 expressed as a GFP miniprotein. Exp Cell Res 265: 234–241
Mau CMS, Nakao Y, Yoshida WY, Scheuer PJ, Kelly-Borges M (1996) Waiakeamide, a cyclic hexapeptide from the sponge Ircinia dendroides. J Org Chem 61: 6302–6304
Mazar AP (2001) The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12: 387–400
McDonald III ER, El-Deiry WS (2000) Cell cycle control as a basis for cancer drug development (review). Int J Oncol 16: 871–886
McElroy Jr EA, Pïtot HC, Erlichman C, Reid JM, Ames MM, Windebank AJ, Sloan JA, Rubin J (1997) Phase I trial of dolastatin 10 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 16: 223a
McKelvey DR, Brooks CL, Mokotoff M (1991) A CHARMM analysis of the conformations of the metastasis-inhibiting laminin pentapeptide. J Protein Chem 10: 265–271
Medina OP, Söderlund T, Laakkonen LJ, Tuominen EK, Koivunen E, Kinnunen PK (2001) Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res 61: 3978– 3985
Mesfin FB, Andersen TT, Jacobson HI, Zhu S, Bennett JA (2001) Development of a synthetic cyclized peptide derived from a- fetoprotein that prevents the growth of human breast cancer. J Pept Res 58: 246–256
Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19: 2312–2323
Mikhailova AA, Gerasimova GK, Treshchalina EM, Strelkov LA, Fonina LA, Gur’yanov SA (1998) Antitumor action of myelopeptide-2. Ross Khim Zh 42: 176–178. See Chem Abstr 132: 30429h
Milne PJ, Hunt AL, Rostoll K, Van Der Walt JJ, Graz CJM (1998) The biological activity of selected cyclic dipeptides. J Pharm Pharmacol 50: 1331–1337
Mishima K, Mazar AP, Gown A, Skelly M, Ji X-D, Wang X-D, Jones TR, Cavenee WK, Huang H-JS (2000) A peptide derived from the non-receptor binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci USA 97: 8484– 8489
Mittelman A, Chun HG, Puccio C, Coombe N, Lansen T, Ahmed T (1999) Phase II clinical trial of didemnin in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiform (NSC 325319). Invest New Drugs 17: 179–182
Miyamoto Y, Kuroda M, Munekata E, Masaki T (1986) Stochiometry of actin and phalloidin binding: one molecule of the toxin dominates two actin subunits. J Biochem 100: 1677–1680 Mizejewski GJ (2001) Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction. Expert Opin Invest Drugs 10: 1063–1073
Mizuguchi H, Kubomi T, Nomura R, Yasukawa K, Imanaka T, Takagi M (2000) Screening of an oligopeptide antagonist for interleukin-6 from a random phage library. Biotechnol Lett 22: 1015–1020
Molineaux CJ, Sluss PM, Bree MP, Gefter ML, Sullivan LM, Garnick MB (1998) Suppression of plasma gonadotropins by anarelix, a potent new LHRH antagonist. Mol Urol 2: 265–268
Montgomery AMP, Reisfeld RA, Cheresh DA (1994) Integrin αvβ3 rescues melanoma cells from apoptosis in 3-dimentional dermal collagen. Proc Natl Acad Sci USA 91: 8856–8860
Mooberry SL, Taoka CR, Busquets L (1996) Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site. Cancer Lett 107: 53–57
Moody TW, Pert CB, Gazdar AF, Carney DN, Minna JD (1981) High levels of intracellular bombesin characterize human smallcell lung carcinoma. Science 214: 1246–1248
Moody TW, Zia F, Draoui M, Brennemen D, Fridkin M, Davidson A, Gozes I (1993) A vasoactive intestinal peptide antagonist inhibits non small cell lung cancer growth. Proc Natl Acad Sci USA 90: 4345–4349
Moore RE, Corbett TH, Patterson GML, Valeriote FA (1996) The search for new antitumor drugs from blue-green algae. Curr Pharm Des 2: 317–330
Moore RE, Entzeroth M (1988) Majusculamide D and deoxymajusculamide D, two cytotoxins from Lyngbya majuscula. Phytochemistry 27: 3101–3103
Morgan BA, Sadat-Aalaee D (2001) Somatostatin receptor type 5 agonist cyclic peptide, their preparation, and their therapeutic use. Patent WO 01 00,676. See Chem Abstr 134: 80825w
Mori H, Komazawa H, Saiki I, Azuma I (1994) Preparation of peptide derivatives for inhibition of cancer metastasis. Patent JP 05,97,890. See Chem Abstr 120: 192311t
Mori H, Komazawa H, Kojima M, Saiki I, Azuma I (1995a) Preparation of peptide derivatives as cancer metastasis inhibitors. Patent JP 06,321,985 and 06,321,987. See Chem Abstr 122: 133866w and 133867x
Mori H, Komazawa H, Saiki I, Azuma I (1995b) Preparation of pentapeptides for inhibitions of cancer metastasis. Patent JP 06,41,193. See Chem Abstr 122: 10684c
Mori H, Sakamoto K, Tsurumi Y, Takase S, Hino M (2000) Cyclic tetrapeptide compounds as histone deacetylase and their use in therapy. Patent WO 00 21,979. See Chem Abstr 132: 288796d
Morita H, Nagashima S, Takeya K, Itokawa H (1993) Astins A and B, antitumor cyclic pentapeptides from Aster tataricus. Chem Pharm Bull 41: 992–993
Morita H, Gonda A, Takeya K, Itokawa H (1996a) Cycloleonuripeptide A, B and C, three new proline-rich cyclic nonapeptides from Leonurus heterophyllus. Bioorg Med Chem Lett 6: 767–770
Morita H, Kayashita T, Shimomura M, Takeya K, Itokawa H (1996b) Cyclic peptide from higher plants. 24. Yunnanin C, a novel cyclic heptapeptide from Stellaria yunnanensis. J Nat Prod 59: 280–282
Morita H, Nagashima S, Uchiumi Y, Kuroki O, Takeya K, Itokawa H (1996c) Cyclic peptides from higher plants. 28. Antitumor activity and hepatic microsomal biotransformation of cyclic pentapeptides, astins, from Aster tataricus. Chem Pharm Bull 44: 1026–1032
Morita H, Shimbo K, Shigemori H, Kobayashi J (2000) Antimitotic activity of moroidin, a bicyclic peptide from the seeds of Celosia argentea. Bioorg Med Chem Lett 10: 469–471
Mosher C, Gothesis of [4',4'-bis(glycine),5',5'- bis(valine)]actinomycin D, a tetra-N-demethylactinomycin. J Org Chem 37: 2928–2933
Mueller H (1998) Tumor necrosis factor as an antineoplastie agent: pitfalls and promises. Cell Mol Life Sci 54: 1291–1298
Muller R, Kontermann RE, Montigiani S (2000) Transcription factor E2F DNA-binding domain inhibitor peptides and uses thereof. Patent WO 00 44,771. See Chem Abstr 133: 145915b
Murphy WA, Heiman ML, Lance VA, Mezo I, Coy DH (1985) Octapeptide analogs of somatostatin exhibiting greatly enhanced in vivo and in vitro inhibition of growth hormone secretion in the rat. Biochem Biophys Res Commun 132: 922–928
Mutou T, Kondo T, Ojika M, Yamada K (1996a) Isolation and stereostructures of dolastatin G and nordolastatin G, cytotoxic 35-membered cyclodepsipeptides from the Japanese sea hare Dolabella auricularia. J Org Chem 61: 6340–6345
Mutou T, Kondo T, Shibata M, Ojika M, Kigoshi H, Yamada K (1996b) Synthesis of dolastatin G and nordolastatin G, cytotoxic 35-membered cyclodepsipeptides of marine origin. Tetrahedron Lett 37: 7299–7302
Mutou T, Suenaga K, Fujita T, Itoh T, Takada N, Hayamizu K, Kigoshi H, Yamada K (1997) Enantioselective synthesis of aurilide, a cytotoxic 26-membered cyclodepsipeptide of marine origin. Synlett 199–201
Nagalla SR, Barry BJ, Creswick KC, Eden P, Taylor JT, Spindel ER (1995) Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA 92: 6205–6209
Nakagawa M, Hayakawa Y, Furihata K, Seto H (1990) Structural studies on new depsipeptide antibiotics, variapeptin and citropeptin. J Antibiot 43: 477–484
Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126–133
Namikoshi M, Rinehart KL, Sakai R, Stotts RR, Dahlem AM, Beasley VR, Carmichael WW, Evans WR (1992) Identification of 12 hepatotoxins from a homer lake bloom of the cyanobacteria Microcystis aeruginosa, Microcystis viridis and Microcystis wesenbergii: nine new mycrocystins. J Org Chem 57: 866–872
Nassar N, Horn G, Herrmann C, Scherer A, McCormick F, Wittinghofer A (1995) The 2.2 Å crystal structure of the Rasbinding domain of the Serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375: 554–560
Nestor JJ, Moffatt JG, Sima JM (1985) Nona- and dodecapeptides for augmenting natural killer cell activity. Patent US 4,473,555. See Chem Abstr 102: 113959n
Nestor JJJ, Tahilramani R, Ho TL, Goodpasture JC, Vickery BH, Ferrandon P (1992) Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 35: 3942–3948
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9–22
Nevins JR (2001) The Rb/E2F pathway and cancer. Human Mol Gen 10: 699–703
Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, Lim WA (1998) Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science 282: 2088–2092
Niehof M, Radziwill G, Klauser S, Moelling K (1995) A small peptide derived from aminoterminus of c-Raf-1 inhibits c-Raf-1/Ras binding. Biochem Biophys Res Commun 206: 46–50
Nogle LM, Williamson RT, Gerwick WH (2001) Somamides A and B, two new depsipeptide analogues of dolastatin 13 from a Fijian cyanobacterial assemblage of Lyngbya majuscula and Schizothrix species. J Nat Prod 64: 716–719
Nomizu M, Kuratomi Y, Song SY, Ponce ML, Hoffman MP, Powell SK, Miyoshi K, Otaka A, Kleinman HK, Yamada Y (1997) Identification of cell binding sequences in mouse laminin ?1 chain by systematic peptide screening. J Biol Chem 272: 32198–32205
Norman BH, Shih C (1998) Tripeptide and tetrapeptide pharmaceutical compounds. Patent WO 98 38,178. See Chem Abstr 129: 216922g
Nuijen B, Bouma M, Henrar RE, Manada C, Bult A, Beijnen JH (1999) Compatibility and stability of aplidine, a novel marinederived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration. Anti-Cancer Drugs 10: 879–887
Nyeki O, Rill A, Schon I, Orosz A, Schrett J, Bartha L, Nagy J (1998) Synthesis of peptide and pseudopeptide amides inhibiting the proliferation of small cell and epithelial types of lung carcinoma cells. J Pept Sci 4: 486–495
O I, Kieber-Emmons T, Otvos L, Blaszcyk-Thurin M (1999) Peptides mimicking sialyl-Lewis A isolated from a random peptide library and peptide array. Ann NY Acad Sci 886: 276–279
Oberg K (2001) Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 47 [Suppl 2]: 40–53
Ohki-Hamazaki H (2000) Neuromedin B. Prog Neurobiol (Oxford) 62: 297–312
Ohlsson B, Fredang N, Axelson J (1999) The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines. Scand J Gastroenterol 34: 1224–1229
Ohnishi M, Yamaki-Kataoka Y, Kariya K, Tamada M, Hu C-D, Kataoka T (1998) Selective inhibition of Ras interaction with its particular effector by synthetic peptides corresponding to the Ras effector region. J Biol Chem 273: 10210–10215
Okada H, Suzuki H, Yoshinari T, Arakawa H, Okura A, Suda H (1994) A new topoisomerase II inhibitor, BE-22179, produced by a Streptomycete I. Producing strain, fermentation, isolation and biological activity. J Antibiot 47: 129–135
Oligino L, Lung FD, Sastry L, Bigelow J, Cao T, Curran M, Burke TRJ, Wang S, Krag D, Roller PP, King CR (1997) Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain. J Biol Chem 272: 29046–29052
Olsen RK, Apparao S, Bhat KL (1986) Synthesis of a model analogue of the cyclic decadepsipeptide intercalating agent luzopeptin A (antibiotic BBM 928A) containing proline, valine and unsubstituted quinoline constituents. J Org Chem 51: 3079– 3085
Omer CA, Kohl NE (1997) CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends Pharmacol Sci 18: 437–444
Omura S, Fujimoto T, Otoguro K, Matsuzaki K, Moriguchi R, Tanaka H, Sasaki Y (1991a) Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot 44: 113–116
Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, Nakagawa A (1991b) Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot 44: 117–118
Oppenheim JJ, Murphy WJ, Chertov O, Schirrmacher V, Wang JM (1997) Prospects for cytokine and chemokine biotherapy. Clin Cancer Res 3: 2682–2686
Orosz A (2001) Small peptide amides inhibiting the proliferation of cancer cells. Patent WO 01 85,195. See Chem Abstr 135: 366723f
Orosz A, Nyeki O, Schon I, Kisfaludy L, Schrett J, Bartha L, Nagy J, Ril A, Balogh G (1994) Preparation of small peptide and pseudopeptide amides inhibiting the proliferation of small-cell and epithelial-cell lung cancer cell. Patent EP 556,962. See Chem Abstr 120: 77642q
Orosz A, Schrett J, Nagy J, Bartha L, Schon I, Nyeki O (1995) New short-chain analogs of a substance-P antagonist inhibit proliferation of human small-cell lung-cancer cells in vitro and in vivo. Int J Cancer 60: 82–87
Otsuka H, ShÕji J (1965) The structure of triostin C. Tetrahedron 21: 2931–2938
Otsuka H, Shoji J, Kawano K, Kyogoku Y (1976) Structure confirmation of triostin A by lH and 13C magnetic resonance. J Antibiot 29: 107–110
Otto H-H, Schirmeister T (1997) Cysteine proteases and their inhibitors. Chem Rev 97: 133–171
Packard BS (1987) Identification of a synthetic nonapeptide sequence that inhibits motility in culture of a melanoma subclone that possesses a high metastatic potential. Proc Natl Acad Sci USA 84: 9015–9019
Pacofsky GJ, Lackey K, Alligood KJ, Berman J, Charifson PS, Crosby RM, Dorsey GFJ, Feldman PL, Gilmer TM, Hummel CW, Jordan SR, Mohr C, Shewchuk LM, Sternbach DD, Rodriguez M (1998) Potent dipeptide inhibitors of the pp60c-src SH2 domain. J Med Chem 41: 1894–1908
Pasqualini R, Koivunen E, Ruoslahti E (1995) A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol 130: 1189–1196
Patel VF, Andis SL, Kennedy JH, Ray JE, Schultz RM (1999) Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment “B” analogues. J Med Chem 42: 2588–2603
Patel VF, Hoard DW, Moher ED, Norman BH (1998) Selective epoxidation process for preparation of cryptophycin compounds and intermediates. Patent EP 861,839. See Chem Abstr 129: 216920e
Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB (1995) Minireview. The somatostatin receptor family. Life Sci 57: 1249–1265
Paulsen JE (1993) The synthetic colon peptide pyroGlu-His-GlyOH inhibits growth of human colon carcinoma cells (HT-29) transplanted subcutaneously into athymic mice. Carcinogenesis 14: 1719–1721
Paulsen JE, Hall KS, Rugstad HE, Reichelt KL, Elgo K (1992) The synthetic hepatic peptides Pyr-Glu-Gly-Ser-Asp and Pyr-Glu- Glu-Gly-Ser-Asp acid inhibit growth of MH1C1 rat hepatoma cells transplanted into buffalo rats or athymic mice. Cancer Res 53: 1218–1221
Pawson T, Schlessinger J (1993) SH2 and SH3 domains. Curr Biol 3: 432–434
Pérez Baz J, Cañedo LM, Fernández Puentes JL, Silva Elipe MV (1997) Thiocoraline, a novel depsipeptide with antitumor activity produced by a marine Micromonospora II. Physico-chemical properties and structure determination. J Antibiot 50: 738– 741
Pero SC, Oligino L, Daly RJ, Soden AL, Liu C, Roller PP, Li P, Krag DN (2002) Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J Biol Chem 277: 119–11926
Perrin D, Halazy S, Hill BT (1996) Inhibitors of the Ras signal transduction pathway as potential antitumor agents. J Enzyme Inhib 11: 77–95
Petit T, Davidson KK, Lawrence RA, von Hoff DD, Izbicka E (2001) Neuropeptide receptor status in human tumor cell lines. Anti-Cancer Drugs 12: 133–136
Pettit GR (1997) The dolastatins. Fortschr. Chem Org Naturst 70: 1– 79
Pettit GR, Kamano Y, Holzapfel CW, van Zyl WJ, Tuinman AA, Herald CL, Baczynskyj L, Schmidt JM (1987) The structure and synthesis of dolastatin 3. J Am Chem Soc 109: 7581–7582
Pettit GR, Kamano Y, Dufresne C, Cerny RL, Herald CL, Schmidt JM (1989a) Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 54: 6005–6006
Pettit GR, Kamano Y, Herald CL, Dufresne C, Cerny RL, Herald DL, Schmidt JM, Kizu H (1989b) Isolation and structure of the cytostatic depsipeptide dolastatin 13 from the sea hare Dolabella auricularia. J Am Chem Soc 111: 5015–5017
Pettit GR, Kamano Y, Herald CL, Dufresne C, Bates RB, Schmidt JM, Cerny RL, Kizu H (1990) Antineoplastic agents. 190. Isolation and structure of the cyclodepsipeptide dolastatin 14. J Org Chem 55: 2989–2990
Pettit GR, Xu J-P, Hogan F, Williams MD, Doubek DL, Schmidt JM, Cerny RL, Boyd MR (1997a) Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16. J Nat Prod 60: 752–754
Pettit GR, Xu J-P, Williams MD, Hogan F, Schmidt JM, Cerny RL (1997b) Antineoplastic agent 370. Isolation and structure of dolastatin 18. Bioorg Med Chem Lett 7: 827–832
Pettit GR, Flahive EJ, Boyd MR, Bai R, Hamel E, Pettit RK, Schmidt JM (1998a) Antineoplastic agent 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications. Anti-Cancer Drug Des 13: 47–66
Pettit GR, Xu J-P, Hogan F, Cerny RL (1998b) Isolation and structure of dolastatin 17. Heterocycles 47: 491–496
Pickart LR (1989) Glycyl-L-histidyl-lysine copper complexes, their preparation and use as neoplasm inhibitors. Patent WO 88 08,715. See Chem Abstr 111: 70958c
Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865–2868
Piossek C, Schneider-Mergener J, Schirner M, Vakalopoulou E, Germeroth L, Thierauch KH (1999) Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF. J Biol Chem 274: 5612–5619
Plummer MS, Holland DR, Sharipour A, Lunney EA, Fergus JH, Marks JS, McConnell P, Mueller WT, Sawyer TK (1997) Design, synthesis and cocrystal structure of a nonpeptide src SH2 domain ligand. J Med Chem 40: 3719–3725
Poncet J (1999) The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des 5: 139–162
Preston SR, Miller GV, Primrose JN (1996) Bombesin-like peptides and cancer. Crit Rev Oncology-Hematology 23: 225–238
Quigley GJ, Ughetto G, van der marel GA, van Boom JH, Wang AH-J, Rich A (1986) Non-Watson-Crick G.C and A.T base pairs in a DNA-antibiotic complex. Science 232: 1255–1259
Qureshi A, Colin PL, Faulkner DJ (2000) Microsclerodermins F-I, antitumor and antifungal cyclic peptides from the lithistid sponge Microscleroderma sp. Tetrahedron 56: 3679–3685
Radulescu RT, Jacques G (2000) Selective inhibition of human lung cancer cell growth by peptides derived from retinoblastoma protein. Biochem Biophys Res Commun 267: 71–76
Radulovic S, Cai R-Z, Serfoso P, Groot K, Redding TW, Pinski J, Schally AV (1991) Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Prot Res 38: 593–600
Randazzo A, Dal Piaz F, Orrù S, Debitus C, Roussakis C, Pucci P, Gomez-Paloma L (1998) Axinellins A and B: new prolinecontaining antiproliferative cyclopeptides from the Vanuatu sponge Axinella carteri. Eur J Org Chem 2659–2665
Rashid MA, Gustafson KR, Boswell JL, Boyd MR (2000) Haligramides A and B, two new cytotoxic hexapeptides from the marine sponge Haliclona nigra. J Nat Prod 63: 956–959
Raymond E, Ady-Vago N, Ribarg V, Faivres S, Lecot F, Wright T, Lopez-Lazaro L, Guzman C, Jimeno J, Armand JP (2000) Phase I and pharmacokinetics study of aplidine, a marine derived compound, given as a 24h infusion every 2 weeks in patients with advanced solid tumors and non-Hodgkin lymphoma (NHL). Ann Oncol 11 (S4): 134
Raynor K, Murphy WA, Coy DH, Taylor JE, Moreau J-P, Yasuda K, Bell GI, Reisine T (1993) Cloned somatostatin receptor: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol 43: 838–844
Reeves R, Nissen MS (1990) The AT-DNA-binding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 265: 8573–8582
Reichlin S (1983) Somatostatin. N Engl J Med 309: 1556–1563 Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC (2002) Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98: 682–689
Reile H, R.-Z. C, Armatis P, Schally AV (1995) New antagonists of bombesin/gastrin-releasing peptide with C-terminal Leu (CH2N)Tac-NH2. Int J Oncol 7: 749–754
Reissmann T, Engel J, Kuscher B, Bernd M, Hilgard P, Peukert M, Szeleny I, Reichert S, Gonzalez-Barcena D, Nieschlag E, Comaru-Schally AM, Schally AV (1994) Cetrorelix. Drugs Future 19: 228–237
Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K, Czompoly T (2000) Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro. Proc Natl Acad Sci USA 97: 1218–1223
Reuning U, Magdolen V, Wilhelm O, Fisher K, Lutz VHG, Schmitt M (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13: 893–906
Richter JD, Mendez R (2001) CPEB-derived peptides blocking Eg2 kinase activity and their therapeutic uses. Patent WO 01 07,466. See Chem Abstr 134: 143865g
Ridge RJ, Sloane NH (1996) Partial N-terminal amino acid sequence of the anti-neoplastic urinary protein (ANUP) and the anti-tumour effect of the N-terminal nonapeptide of the unique cytokine present in human granulocytes. Cytokine 8: 1–5
Rinehart Jr KL, Gloer JB, Cook JC, Miszak SA, Scahill TA (1981a) Structures of the didemnins, antiviral and cytotoxic depsipeptides from a Caribbean tunicate. J Am Chem Soc 103: 1857–1859
Rinehart Jr KL, Gloer JB, Hughes Jr. RG, Renis HE, McGovern JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH (1981b) Didemnins: antiviral and antitumer depsipeptides from a Caribbean tunicate. Science 212: 933–935
Rinehart Jr KL, Kishore V, Bible KC, Sakai R, Sullins DW, Li K-M (1988) Didemnins and tunichlorin: novel natural products from the marine tunicate Trididemnum solidum. J Nat Prod 51: 1–21
Rivier J, Porter J, Rivier C, Perrin M, Corrigan AZ, Hook WA, Siraganian RP, Vale WW (1986) New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J Med Chem 29: 1846–1851
Rochefort H, Liaudet-Coopman E (1999) Cathepsin D in cancer metastasis: a protease and a ligand. APMIS 107: 86–95
Ruhenstroth-Bauer G (1994) Peptide inhibitor of liver cell proliferation. Patent DE 4,224,509. See Chem Abstr 120: 183012u
Ruhenstroth-Bauer G (1997) Tripeptide for inhibiting the proliferation rate of hepatocytes. Patent US 5,589,461. See Chem Abstr 126: 139869d
Ruhenstroth-Bauer G, Vogl S, Voelter W, Goldberg M, Topic E (1993) Ser Asp Lys-Ac, a strong inhibitor of liver cell proliferation. Naturwissenschaften 80: 314–315
Ruoslahti E, Reed JC (1994) Anchorage dependence, integrins and apoptosis. Cell 77: 477–478
Ryan RR, Weber HC, Hou W, Sainz E, Mantey SA, Battey JF, Coy DH, Jensen RT (1998) Ability of various bombesin receptor agonists and antagonists to alter intracellular signalling of the human orphan receptor BRS-3. J Biol Chem 273: 13613– 13624
Ryu G, Matsunaga S, Fusetani N (1994a) Discodermins E, a cytotoxic and antimicrobial tetradecapeptide from the marine sponge Discodermia kiiensis. Tetrahedron Lett 35: 8251–8254
Ryu G, Matsunaga S, Fusetani N (1994b) Discodermins F-H, cytotoxic and antimicrobial tetradecapeptides from the marine sponge discodermia kiiensis: structure revision of Discodermins A-D. Tetrahedron 50: 13409–13416
Sagami (1984) Hexapeptides. Patent JP 84,152,356. See Chem Abstr 102: 25047h
Sainz E, Akeson M, Mantey SA, Jensen RT, Battey JF (1998) Four amino acid residues are critical for high affinity binding ofneuromedin B to the neuromedin B receptor. J Biol Chem 273: 15927–15932
Sakai Y, Yoshida T, Tsujita T, Ochiai K, Agatsuma T, Saitoh Y, Tanaka F, Akiyama T, Akinaga S, Mizukami T (1997) GE3, a novel hexadepsipeptide antitumor antibiotic, produced by Streptomyces sp. I. Taxonomy, production, isolation, physico-chemical properties, and biological activities. J Antibiot 50: 659–664
Samy R, Kim HY, Brady M, Toogood PL (1999) Total synthesis of motuporin and 5-[L-Ala]-motuporin. J Org Chem 64: 2711– 2728
Sanz-Cervera JF, Stocking EM, Usui T, Osada H, Williams RM (2000) Synthesis and evaluation of microtubule assembly inhibition and cytotoxicity of prenylated derivatives of cyclo-L-Trp-LPro. Bioorg Med Chem 8: 2407–2415
Sasse F, Steinmetz H, Heil J, Hoefle G (2000) Tubulysins, new cytostatic peptides from Myxobacteria acting of microtubuli. Production, isolation, physiochemical and biological properties. J Antibiot 53: 879–885
Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW (1997) Structure of BCL-XL-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983–986
Sawa E, Takahashi M, Kamishohara M, Tazunoki T, Kimura K, Arai M, Miyazaki T, Kataoka S, Nishitoba T (1999) Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding. J Med Chem 42: 3289– 3299
Sawyer TK (1998) Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers 47: 243–261
Schally AV (1999) Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20: 1247–1262
Schasteen CS (1991) Preparation of a peptide with anti-metastasis activity. Patent EP 397, 635. See Chem Abstr 114: 186076e Schatz PJ, Chen M-J, Piplani S, Mozsgai CA, Balu P (2001) Peptide compounds having affinity for the vascular endothelial growth factor receptor-2 (VEGFR-2) and associated uses. Patent WO 01 83,693. See Chem Abstr 135: 366772w
Schiavi B, Richard DJ, Jouillé MM (2002) Total synthesis of isoroquefortine C. J Org Chem 67: 620–624
Schimmer AD, Hedley DW, Chow S, Pham NA, Chakrabartty A, Bouchard D, Mak TW, Trus MR, Minden MD (2001) The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2. Cell Death Differ 8: 725–733
Schindler-Horvat JE, Fairchild DG, Hasler C, Tamaszewski JE, Donohue SJ, Tyson CA (1998) Toxicity of jasplakinohide (NSC 613009) in rats and dogs. Proc Am Assoc Cancer Res 39: 597
Schmidt U, Griesser H, Haas G, Kroner M, Riedl B, Schumacher A, Sutoris F, Haupt A, Emling F (1999) Synthesis and cytostatic activities of didemnin derivatives. J Pept Res 54: 146–161
Scholar EM, Violi L, Hexum TD (1987) The antimetastatic activity of enkephahin-like peptides. Cancer Lett 35: 133–138
Sebti SM, Hamilton AD (1997) Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol Ther 74: 103–114
Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from p53 C-terminal domain. Nat Med 3: 632–638
Sethi T, Langdon S, Smyth J, Rozengurt E (1992) Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res 52 (9, Suppl.): 2737s–2742s
Shakespeare WC (2001) SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 5: 409–415
Sheh L, Cheng JY, Kuan YH, Chen CF (1990) Synthesis of a cyclic hexapeptide with sequence corresponding to murine tumor necrosis factor-(127–132) as a novel potential antitumor agent. Int J Pept Prot Res 36: 104–108
Sheh L, Lin HH, Jeng KCG, Chen CF (1993) Studies of the synthesis, immunology and cytotoxicity of a cyclic octapeptide corresponding to TNF-a-(59–66). J Med Chem 36: 4302–4307
Sheppeck JE, Gauss C-M, Chamberlin AR (1997) Inhibition of the Ser-Thr phosphatase PP1 and PP2A by naturally occurring toxins. Bioorg Med Chem 5: 1739–1750
Shibata K, Yamasaki M, Yoshida T, Mizukami T (1998) Preparation of E2F activity inhibitory peptide compounds. Patent WO.98 14,474. See Chem Abstr 128: 283089h
Shibata K, Yamasaki M, Yoshida T, Mizukami T, Shinkai A, Anazawa H (1999) Preparation of peptides having cyclic structures and exerting p53 protein activity-restoring effect on p53 protein mutants. Patent WO 98 51,707. See Chem Abstr 130: 4096m
Shih C, Williams DC (1998) Preparation of cryptophycin compounds in combination with synchronizing or activating agents for treating cancer. Patent EP 870,506. See Chem Abstr 129: 302893e
Shih C, Gossett LS, Gruber JM, Grossman CS, Andis SL, Schultz RM, Worzalla JF, Corbett TH, Metz JT (1999) Synthesis and biological evaluation of novel cryptophycin analogs with modification in the β-alanine region. Bioorg Med Chem Lett 9: 69–74
Shin SY, Kang JH, Hahm K-S (1999) Structure-antibacterial antitumor and hemolytic activity relationships of cecropin Amagainin 2 and cecropin A-melittin hybrid peptides. J Pept Res 53: 82–90
Shioiri T, Hamada Y, Kato S, Shibata M, Kondo Y, Nakagawa H, Kohda K (1987) Cytotoxic activity of cyclic peptides of marine origin and their derivatives: importance of oxazoline functions. Biochem Pharmacol 36: 4181–4185
Shute RE, Dunlap B, Rich DH (1987) Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides. J Med Chem 30: 71– 78
Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BHB, Crews CM (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9: 2283–2288
Singh SB, Zink DL, Polishook JD, Dombrowski AW, Darkin- Rattray SJ, Schmatz DM, Goetz MA (1996) Apicidins: novel tetrapeptides as coccidiostats and antimalarial agents from Fusarium pallidoroseum. Tetrahedron Lett 37: 8077–8080 Sirdeshpande BV, Toogood PL (1995) Inhibition of protein synthesis by RA-VII. Bioorg Chem 23: 460–470
Sloane NH (2002) Sixteen residue amino-terminal fragment of the antineoplastic protein (ANUP) as a pharmacologically active antitumor agent. Patent US 2002 61,851. See Chem Abstr 136: 380093c
Smith CD, Zhang X (1996) Mechanism of action of cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. J Biol Chem 271: 6192–6198
Smitka TA, Deeter JB, Hunt AH, Mertz F, Ellis RM, Boeck LD, Yao RC (1988) A83586C, a new depsipeptide antibiotic. J Antibiot 41: 726–733
Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR (1994) Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group. Anti-Cancer Drugs 5: 147–150
Sone H, Nemoto T, Ishiwata H, Ojika M, Yamada K (1993a) Isolation, structures and synthesis of dolastatin D, a cytotoxic38 Y. L. Janin cyclic depsipeptide from the sea hare Dolabella auricularia. Tetrahedron Lett 34: 8449–8452
Sone H, Nemoto T, Ojika M, Yamada K (1993b) Isolation, structure and synthesis of dolastatin C, a new depsipeptide from sea hare Dolabella auricularia. Tetrahedron Lett 34: 8445–8448
Sone H, Shibata T, Fujita T, Ojika M, Yamada K (1996) Dolastatin H and isodolastatin H, potent cytotoxic peptides from the sea hare Dolabella auricularia: isolation, stereostructure and synthesis. J Am Chem Soc 118: 1874–1880
Sorbera LA, Graul A, Castañer J (2001) Cilengitide. Drugs Future 25: 674–678
Strahl BD, Allis CD (2000) The language of covalent histones modifications. Nature 403: 41–45
Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV (2000) A new endogenous differentiating factor (myelopeptide-4) for myeloid cells. FEBS Lett 470: 281–284
Sugawara K, Toda S, Moriyama T, Konishi M, Oki T (1993) Verucopeptin, a new antitumor antibiotic active against B16 melanoma. Structure determination. J Antibiot 46: 928–935
Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP (2000) A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 46: 319–328
Suzuki M (1990) The heptad repeat in the largest subunit of RNA polymerase II binds by intercalating into DNA. Nature 344: 562–565
Szegedi Z, Takacs J, Szende B, Vadasz Z, Horvath A, Gulyas E, Toth G, Petak I, Bocsi J, Keri G (1999) A specifically radiolabelled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells. Endrocrine 10: 25–34
Szekeres T, Fritzer-Szekeres M, Elford HL (1997) The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci 34: 503–528
Tabor AB (1996) Synthesis of a peptide-intercalator hybrid based on the bZIP motif from GCN4. Tetrahedron 52: 2229–2234
Takahashi K, Koshino H, Esumi Y, Tsuda E, Kurosawa K (2001) Sw-163C and E, novel antitumor depsipeptides produced by Streptomyces sp. Part 2. Structure elucidation. J Antibiot 54: 622–627
Takenaka S, Sato H, Itakura Y, Kondo H, Takagi M (1996) Construction of a dimeric DNA-binding peptide model by peptideanthraquinone conjugation. Int J Pept Prot Res 48: 397–400
Takusagawa F (1985) The role of the cyclic depsipeptide rings in antibiotics. J Antibiot 38: 1596–1604
Talanian RV, McKnight J, Rutkowski R, Kim PS (1992) Minimum length of a sequence-specific DNA binding peptide. Biochemistry 31: 6871–6875
Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M (1994) Hemiasterlin and geodiamolides TA; two new cytotoxic peptides from the marine sponge Hemiasterella minor (kirkpatrick). Tetrahedron Lett 35: 4453–4456
Tamura SY, Weinhouse M, Roberts CA, Goldman EA, Masukawa K, Anderson SM, Cohen CR, Bradbury AE, Bernardino VT, Dixon SA, Ma MG, Nolan TB, Brunck TK (2000) Synthesis and biological activity of peptidyl aldehyde urokinase inhibitors. Bioorg Med Chem Lett 10: 983–987
Tan DC, Kini RM, Jois SD, Lim DK, Xin L, Ge R (2001) A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett 494: 150–156
Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408–411
Taylor JE, Bogden AE, Moreau J-P, Coy DH (1988) In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 153: 81–86
Taylor S, Giroux DJ, Jaeckle KA, Panella TJ, Dakhil SR, Schold SC (1999) Phase II study of didemnin B in central nervous system tumors: a Southwest oncology group study. Invest New Drugs 16: 331–332
Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638–2645
Terano H, Tsurumi Y, Setoi H, Hashimoto M, Kohsaka M (1986) Amino acid derivatives. Patent EP 193,904. See Chem Abstr 105: 227347d
Terranova VP, Williams JE, Liotta LA, Martin GR (1984) Modulation of the metastatic activity of melanoma cells by laminin and fibronectin. Science 226: 982–985
Terui Y, Tomizuka H, Mishima Y, Ikeda M, Kasahara T, Uwai M, Mori M, Itoh T, Tanaka M, Yamada M, Shimamura S, Ishizaka Y, Ozawa K, Hatake K (1999) NH2-terminal pentapeptide of endothelial interleukin 8 is responsible for the induction of apoptosis in leukemic cells and has antitumor effect in vivo. Cancer Res 59: 5651–5655
Tew KD (2000) Is there a role for glyoxalase 1 inhibitors as antitumor drugs? Drug Resist. Updates 3: 263–264
Thierry J, Grillon C, Gaudron S, Potier P, Riches A, Wdzieczak- Bakala J (2001) Synthesis and biological evaluation of analogues of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro haematopoietic cell proliferation. J Pept Sci 7: 284–293
Thomas F, Arvelo F, Antoine E, Jacrot M, Poupon MF (1992) Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression. Cancer Res 52: 4872–4877
Toda S, Sugawara K, Nishiyama Y, Ohbayashi M, Ohkusa N, Yamamoto H, Konishi M, Oki T (1990) Quinaldopeptin, a novel antibiotics of the quinomycin family. J Antibiot 43: 796–808
Tokita K, Katsuno T, Hocart SJ, Coy DH, Llinares M, Martinez J, Jensen RT (2001) Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor. J Biol Chem 276: 36652–36663
Tomizaki K-Y, Kate T, Nishino N, Yoshida M, Komatsu Y (1999) Histone deacetylase inhibitors based on trapoxin B. Pept Sci 35th (Pub. 1999): 181–184. See Chem Abstr 131: l30252t
Toske SG, Fenical W (1995) Cyclodidemnamide: a new cyclic heptapeptide from the marine ascidian Didemnum molle. Tetrahedron Lett 36: 8355–8358
Tressler RJ, Pitot PA, Stratton JRL, Forrest LD, Zhuo S, Drummond RJ, Fong S, Doyle MV, Doyle LV, Min HY, Rosenberg S (1999) Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 107: 168–173
Tsuda M, Ishiyama H, Masuko K, Takao T, Shimonishi Y, Kobayashi J (1999) Keramamides M and N, two new cyclic peptides with a sulfate ester from Theonella sponge. Tetrahedron 55: 12543–12548
Tsukamoto S, Painuly P, Young KA, Yang X, Shimizu Y (1993) Microcystilide A: a novel cell-differentiation-promoting depsipeptide from Microcystis aeruginosa NO-15–1840. J Am Chem Soc 115: 11046–11047
Uchihata Y, Ando N, Ikeda Y, Kondo S, Hamada M, Umezawa K (2002) Isolation of a novel cyclic hexadepsipeptide pipalamycin from streptomyces as an apoptosis-inducing agent. J Antibiot 55: 1–5
Ueda I, Niwa M, Uchiyama F, Ono H (1986) Oligopeptides. Patent JP 60,214,768. See Chem Abstr 105: 43331n
Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K (1994a) FR901228, a novel antitumorbicyclic depsipeptide produced by Chromobacterium violaceum No. 968 III. Antitumor activities on experimental tumors in mice. J Antibiot 47: 315–323
Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T,Qkuhara M (1994b) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968 I. Taxonomy, fermentation, isolation, physicochemical and biological properties and antitumor activity. J Antibiot 47: 301–310
Uemoto H, Yahiro Y, Shigemori H, Tsuda M, Takao T, Shimonishi Y, Kobayashi J (1998) Keramamides K and L, new cyclic peptides containing unusual tryptophan residue from Theonella sponge. Tetrahedron 54: 6719–6724
Umehara K, Nakahara K, Kiyoto S, Iwami M, Okamoto M, Tanaka H, Kohsaka M, Aoki H, Imanaka H (1983) Studies on WF-3161, a new antitumor antibiotic. J Antibiot 36: 478–483
Umezawa K, Nakazawa K, Ikeda Y, Naganawa H, Kondo S (1999) Polyoxypeptins A and B produced by Streptomyces: apoptosisinducing cyclic depsipeptides containing the novel amino acid (2S,3R)-3-hydroxy-3-methylproline. J Org Chem 64: 3034– 3038
Umezawa K, Ikeda Y, Uchihata Y, Naganawa H, Kondo S (2000) Chloptosin, an apoptosis-inducing dimeric cyclohexapeptide produced by Streptomyces. J Org Chem 65: 459–463
Usui T, Kondoh M, Cui CB, Mayumi T, Osada H (1998) Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochem J 333: 543–548
Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M (2000) Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 6: 4205–4208
Varga JL, Schally AV, Csernus VJ, Zarandi M, Halmos G, Groot K, Rekasi Z (1999) Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 96: 692– 697
Veber DF, Freidinger RM, Perlow DS, Palaveda WJ, Holly FRW, Strachan G, Nutt RF, Arison BJC, Homnick WC, Randall MS, Glitzer R, Saperstein R, Hirschmann R (1981) A potent cyclic hexapeptide analogue of somatostatin. Nature 292: 55–58
Velders MP, Nieland JD, Rudolf MP, Lovisecek K, Weijzen S, De Visser KE, Macedo MF, Carbone M, Kast WM (1998) Identification of peptides for immunotherapy of cancer. It is still worth the effort. Crit Rev Immunol 18: 7–27
Vera MD, Joullié MM (2002) Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev 22: 102–145 Vervoort H, Fenical W (2000) Tamandarins A and B: new cytotoxic depsipeptides from a Brazilian ascidian of the family Didemnidae. J Org Chem 65: 782–792
Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Van Hoff DD, Rowinsky E (1998) Phase 1 and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. J Clin Oncology 16: 2770–2779
Vince R, Brownell J, Akella LB (1999) Synthesis and activity of g-(L-g-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglydine: a metabolically stable inhibitor of glyoxalase 1. Bioorg Med Chem Lett 9: 853–856
von Angerer E (2000) Tubulin as a target for anticancer drugs. Curr Opin Drugs Discovery Dev 3: 575–584
von Closse A, Huguenin R (1974) Isolierung und strukturaufklärung von chlamydocin. Helv Chim Acta 57: 533– 545
Wadler S, Tenteromano L, Cazenave L, Sparano JA, Greenwald ES, Rozenblit A, Kaleya R, Wiernik PH (1994) Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemother Pharmacol 34: 266–269
Wakita K-I, Minami M, Venkateswarlu A, Sharma VM, Ramesh M, Akahane K (2001) Antitumor bicyclic hexapeptide RA-VII modulates cyclin D1 protein level. Anti-Cancer Drugs 12: 433–439
Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J (1993) Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72: 779–790
Wang J-L, Zhang Z-J, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, Huang Z (2000) Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res 60: 1498–1502
Waring MJ, Wakelin LP (1974) Echinomycin: a bifunctional intercalating antibiotic. Nature 252: 653–657
Watanabe H, Kamata S, Fukuda T (1998) Preparation of tripeptide analogs containing benzoxazepine derivatives as cysteine protease inhibitors. Patent JP 09,295,996. See Chem Abstr 128: 35022x
Webster KR, Coleman KG (1994) Peptide inhibitors of the p33cdk2 and p34cdk2 cell cycle regulatory kinase and human papillomavirus E7 oncoprotein for inhibition of papillomavirusassociated neoplastic transformation. Patent EP 666,270. See Chem Abstr 123: 218395n
Weckbecker G, Raulf F, Stolz B, Bruns C (1993) Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 60: 245–264
Weidle UH, Koenig B (1998) Urokinase receptor antagonists: novel agents for the treatment of cancer. Expert Opin Invest Drugs 7: 391–403
Weinberg RA (1995) The retinoblastoma protein an cell cycle control. Cell 81: 323–330
Wesson KJ, Hamann MT (1996) Keenamide A, a bioactive cyclic peptide from the marine mollusk Pleurobranchus forskalii. J Nat Prod 59: 629–631
White JD, Hong J, Robarge LA (1999) Total Synthesis of Cryptophycins-1,-3–4-24 (Arenastatin A), and -29, cytotoxic depsipeptides from cyanobacteria of the Nostocaceae. J Org Chem 64: 6206–6216
Whittaker M, Floyd CD, Brown P, Gearing AJH (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 99: 2735–2776
Wieland T (1968) Poisonous principle of mushrooms of the genus Amanita. Science 159: 946–952
Wieland T (1987) 50 Jahre Phalloidin. Seine Entdeckung, Characterisierung sowie gegenwärtige und zukünftige Anwendung in der Zellforschung. Naturwissenschaften 74: 367–373
Wieland T, Faulstich H (1978) Amatoxins, phallotoxins, phallolysin, and antamanide: the biologically active components of poisonous Amanita mushrooms. CRC Crit Rev Biochem 5: 185–260
Williams DE, Moore RB, Paul VJ (1989) The structure of ulithiacyclamide B. Antitumor evaluation of cyclic peptides and macrolides from Lissoclinum patella. J Nat Prod 52: 732–739
Williams E, Williams G, Gour BJ, Blaschuk OW, Doherty P (2000) A novel family of cyclic peptide antagonists suggests that Ncadherin specificity is determined by amino acids that flank the HAV motif. J Biol Chem 275: 4007–4012
Williamson MP, Gauvreau D, Williams DH, Waring MJ (1982) Structure and conformation of fourteen antibiotics of the quinoxaline group determined by 1H NMR. J Antibiot 35: 62–66
Wipf P, Miller CP (1992) Total synthesis of westiellamide. J Am Chem Soc 114: 10975–10977
Wipf P, Uto Y (1999) Total synthesis of the putative structure of the marine metabolite trunkamide A. Tetrahedron Lett 40: 5165– 5169
Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241–250
Xu J-X, Jin S (1998) Synthesis and antitumor activities of analogs and segments of Papaver somniferum pollen tridecapeptide. Pept.: Biol Chem., Proc Chin. Pept Symp. 4th 71–74. See Chem Abstr 129: 230985m
Yamaguchi H, Asai A, Mizukami T, Yamashita Y, Akinaga S, Ikeda S, Kanda Y (2000) Preparation of UCK 14A2 derivative as proteasome inhibitors. Patent WO 00 43,000. See Chem Abstr 133: 120677n
Yamasaki L (1999) Balancing proliferation and apoptosis in vivo the goldilocks theory of E2F/DP action. Biochim. Biophys Acta 1423: M9–M15
Yao Z-J, King CR, Kelley J, Milne GW, Voigt JH, Burke Jr TR (1999) Potent inhibition of grb2 SH2 domain binding by nonphosphate- containing ligands. J Med Chem 42: 25–35
Yeung BKS, Nakao Y, Kinnel RB, Carney JR, Yoshida WY, Sceuer PJ, Kelly-Borges M (1996) The kapakahines, cyclic peptides from the marine sponge Cribrochalina olemda. J Org Chem 61: 7168– 7173
Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 [Suppl 1]: S20–S26
Yoshinari T, Okada H, Yamada A, Uemura D, Oka H, Suda H, Okura A (1994) Inhibition of topoisomerase II by a novel antitumor cyclic depsipeptide, BE-22179. Jpn. J Cancer Res 85: 550–555
You S-A, Basu A, Haldar S (1999) Potent antitumor agent proteasome inhibitors; a novel trigger for Bcl2 phosphorylation to induce apoptosis. Int J Oncol 15: 625–628
Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS (2002) Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504–513
Zabriskie TM, Klocke JA, Ireland JM, Marcus AH, Molinski TF, Faulkner DJ, Xu C, Clardy J (1986) Jaspamide, a modified peptide from Jaspis sponge, with insecticidal and antifungal activity. J Am. Chem Soc 108: 3123–3124
Zalacain M, Zaera E, Vázquez D, Jiménez A (1982) The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells. FEBS Lett 148: 95–97
Zampella A, Giannini C, Debitus C, Roussakis C, D’Auria MV (1999) New jaspamide derivatives from the marine sponge Jaspis splendans collected in Vanuatu. J Nat Prod 62: 332–334
Zhang LH, Longley RE (1999) Induction of apoptosis in mouse thymocytes by microcolin A and its synthetic analog. Life Sci 64: 1013–1028
Zhang X, Patel DJ (1991) Solution structure of the luzopeptin-DNA complex. Biochemistry 30: 4026–4041
Zhao M, Kleinman HK, Mokotoff M (1994) Synthetic laminin-like peptides and pseudopeptides as potential antimetastatic agents. J Med Chem 37: 3383–3388
Zhao S, Smith KS, Deveau AM, Dieckhaus CM, Johnson MA, MacDonald TL, Cook JM (2002) Biological activity of the tryprostatins and their diastereoisomers on human carcinoma cell lines. J Med Chem 45: 1559–1562
Zheleva DI, Fischer PM, Mcinnes C, Andrews MJI, Chan WC, Atkinson GE (2002) Cyclin-inhibiting p21 peptides. Patent WO 01 40,142. See Chem Abstr 135: 14300r
Zhu D-M, Uckun FM (2000) Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, induces apoptosis
Author information
Authors and Affiliations
Additional information
Author's address: Dr. Yves Louis Janin, UMR 176 CNRS-Institut Curie, 26 rue d'Ulm, F-75248 Paris cedex 05, France, E-mail: yves.janin@curie.u-psud.fr
Rights and permissions
About this article
Cite this article
Janin, Y. Peptides with anticancer use or potential. Amino Acids 25, 1–40 (2003). https://doi.org/10.1007/s00726-002-0349-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-002-0349-x